documents incorporated reference parts ii iii portions registrants annual report shareholders fiscal year annual report parts iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statementpart item business general segments business consumer pharmaceutical medical devices diagnostics geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis financial condition results operation quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accounting fees services part iv exhibits financial statement schedules signatures report independent registered public accounting firm financial statement schedule exhibit index part item business general johnson johnson subsidiaries approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson operating companies conducting business virtually countries world johnson johnsons primary focus products related human health well johnson johnson incorporated state new jersey companys structure based principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located segments business johnson johnson organized three business segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results managements discussion analysis results operations financial condition pages note segments business geographic areas notes consolidated financial statements annual report filed exhibit report consumer consumer segment includes broad range products used baby kids care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products major brands include aveeno skin care products bandaid brand adhesive bandages carefree pantiliners clean clear teen skin care products johnsons baby adult lines products motrin ib ibuprofen products neutrogena skin hair care products roc skin care products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co rembrandt brand oral care products splenda calorie sweetener stayfree sanitary protection products broad family tylenol acetaminophen products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world fiscal fourth quarter company completed acquisition consumer healthcare business pfizer inc comprising products related selfmedications oral care upperrespiratory health tobacco dependence gastrointestinal health skin care eye care hair growth major brands consumer healthcare business pfizer inc include listerine oral care products nicorette line smoking cessation treatments sudafed cold flu allergy products pharmaceutical pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology products distributed directly retailers wholesalers health care professionals prescription use general public key products pharmaceutical segment include risperdal risperidone risperdal consta risperidone longacting injection treatment symptoms schizophrenia procrit epoetin alfa sold outside us eprex biotechnologyderived product stimulates red blood cell production remicade infliximab monoclonal antibody therapy indicated treat symptoms crohns disease ankylosing spondylitis psoriatic arthritis ulcerative colitis chronic severe plaque psoriasis use treatment rheumatoid arthritis topamax topiramate antiepileptic migraine prevention treatment levaquin levofloxacin floxin ofloxacin antiinfective field duragesicfentanyltransdermal fentanyl transdermal system sold outside us durogesic treatment chronic pain offers novel delivery system ortho evra norelgestrominethinyl estradiol transdermal system first contraceptive patch approved us food drug administration fda ortho tricyclen lo norgestimateethinyl estradiol low dose oral contraceptive concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder natrecor nesiritide product treatment patients acutely decompensated congestive heart failure dyspnea rest minimal activity medical devices diagnostics medical devices diagnostics segment includes broad range products distributed wholesalers hospitals retailers used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses distribution health care professional markets done directly surgical supply dealers geographic areas international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable us activities investment commercial climate influenced restrictive economic policies political uncertainties raw materials raw materials essential johnson johnsons operating companies businesses generally readily available multiple sources patents trademarks johnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business sales companys two largest products risperdalrisperdal consta procriteprex accounted approximately johnson johnsons total revenues respectively fiscal accordingly patents related products believed material johnson johnson whole duragesicfentanyl transdermal fentanyl transdermal system lost basic patent protection subject generic competition united states certain international markets eprex epoetin alfa lost basic patent protection subject generic competition international markets duragesicfentanyl transdermal sales declined billion compared due impact generic competition regarding eprex generic competition limited near term due lack approved generic compounds combined sales duragesicfentanyl transdermal eprex accounted approximately johnson johnsons worldwide sales material patents scheduled expire within next two years related risperdal scheduled expire united states december topamax scheduled expire united states september company submitted data fda order obtain pediatric extension risperdal approved would grant exclusivity united states june topamax patent also carries possibility pediatric extension united states obtained would grant exclusivity united states march johnson johnson made practice selling products trademarks obtaining protection trademarks available means johnson johnsons trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants competition product lines johnson johnson companies compete companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important johnson johnsons success areas business competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance products johnson johnsons consumer businesses involves significant expenditures advertising promotion research development research activities represent significant part johnson johnsons business major research facilities located united states also australia belgium brazil canada china france germany india japan netherlands singapore united kingdom costs worldwide companysponsored research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumers patients excluding inprocess research development charges amounted million million million fiscal years respectively costs charged directly income year incurred environment johnson johnson companies subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnsons compliance requirements past year expected material effect upon capital expenditures cash flows earnings competitive position regulation johnson johnsons business subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation united states drug device diagnostics cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside united states costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care united states implementation medicare prescription drug improvement modernization act deficit reduction act may cause uncertainty reimbursement levels certain product segments regulatory agencies whose purview johnson johnson companies operate administrative powers may subject companies actions product withdrawals recalls seizure products civil criminal sanctions cases johnson johnsons operating companies may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties available information copies johnson johnsons quarterly reports form q annual report current reports form k amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys securities exchange commission sec filings also available companys web site wwwinvestorjnjcomgovernance soon reasonably practicable electronically filed furnished sec sec filings also available secs web site wwwsecgov addition charters audit committee compensation benefits committee nominating corporate governance committee board directors companys principles corporate governance policy business conduct employees code business conduct ethics members board directors executive officers available wwwinvestorjnjcomgovernance web site address provided without charge shareholder submitting written request provided item risk factors applicable item b unresolved staff comments applicable item properties johnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnsons business approximately follows square feet segment thousands consumer pharmaceutical medical devices diagnostics worldwide total within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnsons manufacturing operations outside united states often conducted facilities serve one segment business locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding usa africa asia pacific worldwide total addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business research johnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnsons properties maintained good operating condition repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements annual report filed exhibit report item legal proceedingsthe information set forth note legal proceedings notes consolidated financial statements pages annual report incorporated herein reference filed exhibit report company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson february unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including following executive officers directors incorporated herein reference material captioned election directors proxy statement name age position dominic j caruso member executive committee vice president finance chief financial officera robert j darretta vice chairman board directors member executive committeeb russell c deyo member executive committee vice president general counsel chief compliance officerc kaye fostercheek member executive committee vice president human resourcesd colleen goggins member executive committee worldwide chairman consumer personal care groupe per peterson md phd member executive committee chairman research development pharmaceuticals groupf christine poon vice chairman board directors member executive committee joseph c scodari member executive committee worldwide chairman pharmaceuticals groupg nicholas j valeriani member executive committee worldwide chairman medical devices diagnostics grouph william c weldon chairman board directors chairman executive committee chief executive officer mr j caruso joined company october company acquired centocor inc time acquisition vice president finance centocor mr caruso named vice president finance orthomcneil pharmaceutical inc vice president group finance companys medical devices diagnostics group may december mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer january b mr r j darretta joined company held several accounting finance positions becoming managing director ethicon italy named president iolab corporation became treasurer company mr darretta named vice president finance chief financial officer appointed executive committee appointed executive vice president vice chairman board directors january mr darretta retired position chief financial officer december plans retire company c mr r c deyo joined company became associate general counsel became member executive committee vice president administration vice president general counsel chief compliance officer april ms k fostercheek joined company vice president human resources johnson johnson consumer products companies march named vice president human resources consumer personal care group named member human resources leadership team consumer personal care group operating committee ms fostercheek became member executive committee vice president human resources company january prior joining company ms fostercheek served various human resources management positions pfizer inc years recently supporting pharmaceutical business japan asia africa middle east latin america e ms c goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group f dr p peterson joined company vice president drug discovery rw johnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november dr peterson named chairman research development pharmaceuticals group dr peterson became member executive committee plans retire company g mr j c scodari joined company president centocor company acquired centocor time acquisition president chief operating officer centocor member centocors board directors since december march named company group chairman north american pharmaceutical business became member pharmaceuticals group operating committee march mr scodari named company group chairman biopharmaceutical businesses mr scodari named worldwide chairman pharmaceuticals group became member executive committee march h mr n j valeriani joined company held various positions becoming president ethicon endosurgery inc january named company group chairman ethicon endosurgery additional responsibility johnson johnson medical products medical devices diagnostics business canada became worldwide franchise chairman depuy franchise mr valeriani became member executive committee vice president human resources september february assumed additional responsibilities worldwide chairman diagnostics january mr valeriani appointed worldwide chairman cardiovascular devices diagnostics relinquished human resources responsibilities became worldwide chairman medical devices diagnostics group october part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company information called item incorporated herein reference material captions managements discussion analysis results operations financial condition share repurchase dividends common stock market prices shareholder return performance graphs note common stock stock option plans stock compensation agreements notes consolidated financial statements pages annual report filed exhibit report issuer purchases equity securities common stock purchases open market made part systematic plan meet companys compensation programs march company announced board directors approved stock repurchase program authorizing company buy back billion companys common stock program completed fiscal fourth quarter following table provides information respect common stock purchases company fiscal fourth quarter total number shares purchased part publicly total number ave price paid announced plans fiscal month shares purchased per share programs october october october november november december total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock pursuant repurchase program publicly announced march aggregate shares openmarket transactions outside program item selected financial data information called item incorporated herein reference material captioned summary operations statistical data annual report filed exhibit report item managements discussion analysis financial condition results operation information called item incorporated herein reference narrative tabular graphic material captioned managements discussion analysis results operations financial condition pages annual report filed exhibit report item quantitative qualitative disclosures market risk information called item incorporated herein reference narrative graphic material captioned managements discussion analysis results operations financial condition liquidity capital resources pages annual report filed exhibit report item financial statements supplementary data information called item incorporated herein reference audited consolidated financial statements notes thereto material captioned report independent registered public accounting firm pages annual report filed exhibit report item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits securities exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits securities exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure william c weldon chairman chief executive officer dominic j caruso chief financial officer reviewed participated evaluation based evaluation messrs weldon caruso concluded date evaluation companys disclosure controls procedures effective internal control managements report internal control financial reporting included report item fiscal quarter ended december changes companys internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting december company completed acquisition consumer healthcare business pfizer inc due close proximity completion date acquisition date managements assessment effectiveness companys internal control financial reporting management excluded consumer healthcare business pfizer inc assessment internal control financial reporting total assets consumer healthcare business pfizer inc primarily intangible assets goodwill represented companys total assets fiscal year ended december operating results consumer healthcare business acquired pfizer inc december reported companys financial statements beginning results subsequent acquisition date significant based companys processes assessment described management concluded december companys internal control financial reporting effective managements assessment effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears report independent registered public accounting firm annual report incorporated herein reference filed exhibit report item b information february company announced michael j dormer worldwide chairman medical devices retired company effective immediately part iii item directors executive officers corporate governance information called item incorporated herein reference material captions election directors stock ownership section compliance section b beneficial ownership reporting compliance discussion audit committee caption corporate governance board meetings committees annual meeting attendance board committees proxy statement material captioned executive officers registrant part report companys policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available companys web site wwwinvestorjnjcomgovernance copies available shareholders without charge upon written request secretary companys principal address substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller posted companys web site wwwinvestorjnjcomgovernance within five business days retained web site least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys web site wwwinvestorjnjcomgovernance copies available shareholders without charge upon written request secretary companys principal address substantive amendment code waiver code granted member board directors executive officer posted companys web site wwwinvestorjnjcomgovernance within five business days retained web site least one year item executive compensation information called item incorporated herein reference material captions compensation discussion analysis executive director compensation compensation committee report proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report form k shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent registrant specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material captioned stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements annual report filed exhibit report equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans number shares weighted average number shares issued upon exercise exercise price remaining available outstanding options outstanding future issuance rights options rights equity compensation plans dec dec dec equity compensation plans approved shareholders equity compensation plans approved shareholders total included category following equity compensation plans approved companys shareholders stock option plan stock option plan stock compensation plan longterm incentive plan included category shares common stock issuable various equity compensation plans assumed company upon acquisition following companies alza corporation scios inc innovasive devices inc inverness medical technology inc centocor inc shares listed issuable category issued plans approved shareholders companies prior acquisition assumption plans company time acquisitions options acquire equity acquired company replaced options acquire common stock company stock options equity awards type made plans since assumption plans company stock options equity awards type made plans future shares included column issued plans approved shareholders applicable acquired company shares issuable scios nonofficer stock option plan shares issuable alza nonstatutory plan shares issuable warrants inverness medical plan also included category shares common stock issuable upon exercise outstanding stock options companys stock option plan nonemployee directors column excludes shares reflected column number shares issued upon exercise outstanding options rights dec item certain relationships related transactions director independence information called item incorporated herein reference material captions corporate governance director independence transactions related persons proxy statementitem principal accounting fees services information called item incorporated herein reference material caption ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements following audited consolidated financial statements notes thereto material captioned report independent registered public accounting firm pages annual report incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended december january january dollars millions balance balance beginning payments end period accruals period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million million million recorded contra asset december january january respectively includes million related previously estimated performancebased rebate allowances managed care contracts includes million related previously estimated performancebased rebate allowances managed care contracts signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date w c weldon chairman board directors february chief executive officer director principal executive officer w c weldon r j darretta vice chairman board directors director february r j darretta vice chairman board directors director c poon j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february colemans j g cullen director february j g cullen director e johns director jordan signature title date g langbo director february g langbo l lindquist director february l lindquist l f mullin director february l f mullin c prince director february c prince reinemund director february reinemund satcher director february satcher report independent registered public accounting firm financial statement schedule board directors johnson johnson audits consolidated financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting referred report dated february appearing annual report shareholders johnson johnson report consolidated financial statements assessment incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york february exhibit index reg sk exhibit table description item exhibit ai restated certificate incorporation dated april incorporated herein reference exhibit registrants annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrants annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrants annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants form q quarterly report quarter ended july av certificate amendment restated certificate incorporation company effective april incorporated herein reference exhibit registrants form q quarterly report quarter ended april b bylaws company amended effective june incorporated herein reference exhibit registrants form q quarterly report quarter ended july upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrants annual report year ended december b stock option plan amended incorporated herein reference exhibit b registrants annual report year ended december c stock option plan amended incorporated herein reference exhibit b registrants annual report year ended january stock compensation plan incorporated herein reference exhibit e registrants annual report year ended december e longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file f form stock option certificate restricted shares nonemployee directors certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended july g form restricted stock unit certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended october h executive bonus plan incorporated herein reference exhibit registrants form registration statement filed commission november file executive incentive plan amended incorporated herein reference exhibit f registrants annual report year ended december reg sk exhibit table description item exhibit j domestic deferred compensation certificate extra compensation plan amended incorporated herein reference exhibit g registrants annual report year ended december k deferred fee plan nonemployee directors amended incorporated herein reference exhibit h registrants annual report year ended january l executive income deferral plan amended incorporated herein reference exhibit registrants annual report year ended december excess savings plan incorporated herein reference exhibit j registrants annual report year ended december n supplemental retirement plan incorporated herein reference exhibit h registrants annual report year ended january executive life insurance plan incorporated herein reference exhibit registrants annual report year ended january p stock option gain deferral plan incorporated herein reference exhibit registrants annual report year ended january q estate preservation plan incorporated herein reference exhibit n registrants annual report year ended january r summary compensation arrangements named executive officers directors filed document statement computation ratio earnings fixed charges filed document pages companys annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document management contract compensatory plan copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company exr yexvwrhtm exr summary compensation arrangementsexhibit r summary compensation arrangements named executive officers directors compensation arrangements named executive officers following description compensation arrangements approved compensation benefits committee board directors johnson johnson compensation committee february companys chief executive officer chief financial officer three highly compensated executive officers named executive officers annual base salary compensation committee approved following base salaries effective february named executive officers william c weldon chairman ceo robert j darretta vice chairman retired cfo christine poon vice chairman per peterson chairman rd pharmaceuticals group russell c deyo vice president general counsel chief compliance officer performance bonus compensation committee approved following bonus payments performance divided discretion compensation committee cash common stock fair market value calculated average high low prices new york stock exchange february mr weldon mr darretta ms poon dr peterson mr deyo stock option restricted share unit grants compensation committee approved following stock option restricted share unit rsu grants companys longterm incentive plan stock options granted exercise price fair market value companys common stock date grant options become exercisable february expire february rsus vest february upon rsu holder still employed company date receive one share companys common stock mr darretta dr peterson plan retire therefore receive stock option rsu awards mr weldon stock options rsus mr darretta stock options rsus ms poon stock options rsus dr peterson stock options rsus mr deyo stock options rsus nonequity incentive plan awards compensation committee approved following nonequity incentive plan awards february recognition performance companys certificate extra compensation cec program awards paid retirement termination employment end fiscal year cec value per unit cec unit value preliminary subject increase decrease based performance company mr darretta dr peterson plan retire therefore receive cec awards mr weldon cec units mr darretta cec units ms poon cec units dr peterson cec units mr deyo cec units compensation arrangements nonemployee directors nonemployee director receives annual fee services director addition directors receive service committee board directors chairman committee presiding director paid annual fee longterm incentive plan nonemployee director receives nonretainer equity compensation year form restricted stock value nonemployee director received grant shares restricted stock based upon fair market value common stock company february service board nonemployee director receives onetime grant shares company common stock upon first becoming member board directors ex yexvhtm ex statement computation ratio earnings fixed chargesexhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions fiscal year ended december january january december december determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interest expense capitalization interest total fixed charges ratio earnings fixed charges ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leases ex yexvhtm ex pages company 's annual report shareholders exhibit table contents managements discussion analysis organization business segments results operations analysis sales business segments analysis consolidated earnings provision taxes income liquidity capital resources information cautionary factors may affect future results audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements equity consolidated statements cash flows notes consolidated financial statements managements report internal control financial reporting report independent registered public accounting firm summary operations statistical data shareholder return performance graphs table contents managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment includes broad range products used baby kids care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology areas products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses companys structure based upon principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located product lines company competes companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance companys consumer products involves significant expenditures advertising promotion managements objectives primary objective company achieve superior levels capital efficient profitable growth accomplish companys management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services new products introduced within past five years accounted sales billion sales invested research development increase billion increase reflects managements commitment importance ongoing development new differentiated products services sustain long term growth operating companies located countries company views principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges company committed developing global business leaders drive growth objectives businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholdersunifying management team companys dedicated employees achieving objectives credo credo provides common set values serves constant reminder companys responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry results operations analysis consolidated sales worldwide sales increased billion compared increases sales increases consisted following sales increase due volume price currency total sales us companies billion billion billion represents increase sales international companies billion billion billion represents increase table contents graph fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively graph international geographic regions experienced sales growth consisting europe western hemisphere excluding us asiapacific africa regions sales increases include impact currency fluctuations us dollar foreign currencies positive impacts europe western hemisphere excluding us negative impact asiapacific africa region company customer represented total revenues sales cardinal health mckesson accounted total revenues respectively results benefited inclusion rd week see note annual closing date details company estimated fiscal fourth quarter growth rate enhanced approximately year approximately net earnings impact additional week negligible graph analysis sales business segments consumer segment consumer segment sales billion increase operational growth accounting total growth due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations consumer segment sales growth led strong sales performance skin care baby kids care franchises overthecounter otc pharmaceuticals nutritionals franchise sales billion increase growth led success relaunch tylenol upper respiratory product line products containing phenylephrine instead pseudoephedrine well growth splenda calorie sweeteners partially offset sales declines adult analgesics skin care franchise sales billion representing increase attributable sales growth aveeno johnsons adult suncare newly acquired groupe vendme adult skin care product lines baby kids care franchise sales grew billion strong growth led success powder product lines international markets well cleanser lotion cream product lines us major consumer franchise sales change vs vs dollars millions otc pharmaceuticals nutritionals skin care baby kids care womens health total table contents international markets womens health franchise sales grew billion resulting solid contributions ky stayfree product lines sales franchises grew billion primarily due acquisition rembrandt brand oral care products operating results consumer healthcare business acquired pfizer inc december reported companys financial statements beginning results subsequent acquisition date significant consumer segment sales billion increase operational growth accounting total growth due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations consumer segment sales billion increase operational growth accounting total growth due positive currency impact us sales increased international sales increased due operational gains positive currency impact pharmaceutical segment pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales billion increase international pharmaceutical segment sales billion increase included operational growth related positive impact currency risperdal risperidone medication treats symptoms schizophrenia bipolar mania risperdal consta risperidone long acting injection treats symptoms schizophrenia achieved billion sales increase prior year sales growth positively impacted lower rebates risperdal higher demand risperdal consta us sales risperdal risperdal consta increased billion international sales increased billion october company received approval us food drug administration fda market risperdal treatment irritability associated autistic disorder children adolescents risperdal compound patent scheduled expire us december company submitted pediatric data fda order extend exclusivity june expiration product patent typically results loss market exclusivity result significant reduction sales procrit epoetin alfa eprex epoetin alfa combined sales billion decline compared prior year procrit experienced sales decline due competitors anticompetitive contracting strategy oncology clinics eprex sales increased approval weekly administration recent restoration label subcutaneous administration eprex europe resulted volume gains although eprex patent expired major european markets erythropoietin product approved using biosimilar regulatory pathway several companies made filings using pathway filings review company predict products may approved remicade infliximab biologic approved treatment crohns disease ankylosing spondylitis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis achieved sales billion growth prior year continued growth driven increased demand due expanded indications fiscal third quarter remicade received fda approval treatment adults chronic severe plaque psoriasis topamax topiramate approved adjunctive monotherapy use epilepsy well prophylactic treatment migraines achieved billion sales increase prior year migraine indication key driver sales growth levaquin levofloxacin floxin ofloxacin achieved combined sales billion representing growth prior year growth achieved despite lack growth market duragesic fentanyl transdermal fentanyl transdermal system sales declined billion reduction decline result impact generic competition us certain international markets generic competition us began january hormonal contraceptive franchise sales declined billion reduction ortho major pharmaceutical product revenues change vs vs dollars millions risperdal risperidone risperdal consta risperidone procrit eprex epoetin alfa remicade infliximab topamax topiramate levaquin floxin levofloxacinofloxacin duragesic fentanyl transdermal fentanyl transdermal system aciphex pariet rabeprazole sodium hormonal contraceptives total table contents evra norelgestrominethinyl estradiol first contraceptive patch approved fda experienced significant decline sales result labeling changes negative media coverage concerning product safety sales decline also result continued generic competition oral contraceptives growth ortho tricyclen lo norgestimateethinyl estradiol low dose oral contraceptive partially offset sales decline hormonal contraceptive franchise concertamethylphenidate hcl product treatment attention deficit hyperactivity disorder achieved sales billion representing increase although original concerta patent expired two new concerta patents issued expire present fda approved generic version substitutable concerta abbreviated new drug applications andas generic versions concerta pending may approved time natrecor nesiritide product treatment patients acutely decompensated congestive heart failure dyspnea rest minimal activity experienced significant decline demand due negative media coverage regarding meta analysis selected historical clinical trials company believes data support conclusions medical consumer publications currently approved label natrecor reflects available data date natrecor purchased company resulted recording intangible asset amortized years remaining unamortized intangible value associated natrecor billion end fiscal fourth quarter based current estimate projected future cash flows adjustment intangible asset required company currently conducting several clinical trials natrecor outcomes predicted may impact projections future cash flows company received fda approval prezistatm darunavir antihiv medication invegatm paliperidone extendedrelease tablets new atypical antipsychotic treatment schizophrenia additionally ionsystm fentanyl iontophoretic transdermal system first needlefree patientactivated analgesic system received fda european commission approval jurnistatm prolongedrelease tablets hydromorphone hcl new prescription treatment severe pain received approval european mutual recognition procedure pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales decreased international pharmaceutical segment sales increased included operational growth related positive impact currency pharmaceutical segment sales billion increase due operational growth due positive currency fluctuations us pharmaceutical segment sales increased international pharmaceutical segment sales grew included operational growth related positive impact currency pharmaceutical segment sales included benefit adjustments related previously estimated performance based rebate allowances managed care contracts adjustments less sales medical devices diagnostics segment medical devices diagnostics segment achieved sales billion representing increase prior year operational growth negative impact currency us sales billion increase international sales billion increase operations negative currency impact depuy franchise achieved billion sales increase prior year growth primarily due depuys orthopaedic joint reconstruction products mitek sports medicine products trauma business acquisitions future medical systems sa hand innovations llc also contributed growth cordis franchise achieved sales billion increase sales cypher sirolimuseluting stent largest product cordis franchise relatively flat relatively modest growth cypher sirolimuseluting stent sales caused lower average selling prices negative media regulatory focus concerning drug eluting stents corresponding lack market growth strong performances biosense webster endovascular businesses fiscal third quarter company received fda approval market precise nitinol stent angioguardtm emboli capture guidewire treat carotid artery disease addition company received ce markmajor medical devices diagnostics franchise sales change vs vs dollars millions depuy cordis ethicon endosurgery ethicon lifescan vision care orthoclinical diagnostics total prior year amounts restated conform current presentation table contents approval europe cypher selecttm sirolimuseluting stent use treatment severe arterial disease leg april july cordis cardiology division cordis corporation received warning letters fda regarding good manufacturing practice regulations good clinical practice regulations response warning letters cordis made improvements quality systems provided periodic updates fda clinical warning letter issues resolved fdas satisfaction respect quality system warning letter addition improvement updates cordis juarez mexico stent supplier locations inspected acceptable results fda inspected miami site global quality system including design control system august acceptable results cordis received observations fda inspection fda inspections completed cordis llc san german puerto rico cordis laboratory operations warren new jersey january thereby completing scheduled follow inspections cordis process evaluating reviewing overall results inspections fda ethicon endosurgery franchise achieved sales billion increase major contributor growth continues endocutter sales include products used performing bariatric procedures treatment obesity important focus area franchise strong results achieved success harmonic scalpel ultrasonic cutting coagulating surgical device received approval january expanded indications include plastic surgery also strong growth advanced sterilization products ethicon franchise sales grew reaching billion result solid growth mesh womens health urology products sales gynecare products dermabond strong results also continued growth suture sales lifescan franchise achieved billion sales increase animas corporation acquired fiscal first quarter provided lifescan platform entry insulin pump segment diabetes market key contributor growth strong performance also achieved onetouch ultra product line us international markets sales vision care franchise reached billion growth rate prior year growth led global success acuvue oasystm brand contact lenses hydracleartm plus acuvue advancetm astigmatism international success day acuvue moisttm acuvue definetm orthoclinical diagnostics franchise achieved billion sales increase growth achieved clinical laboratory immunohematology sales us international markets medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion billion earned increase billion percent sales consolidated earnings provision taxes income improvement change percent sales improvement sections follow highlight significant components changes consolidated earnings provision taxes income cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows salescost products sold percent point increasedecrease prior year selling marketing administrative expenses percent point increasedecrease prior year increase percent sales cost products sold due unfavorable product mix higher manufacturing costs pharmaceutical consumer segments decrease percent sales selling marketing administrative expenses result leveraging selling expenses reduction advertising promotional spending company continued focus controlling expenses decrease percent sales cost products sold due lower manufacturing costs primarily related cypher sirolimuseluting stent well ongoing cost containment activity across organization partially offset negative impact pharmaceutical product mix also decrease percent sales selling marketing administrative expenses due cost containment initiatives pharmaceutical segment partially offset increases investment spending medical devices diagnostics segment decrease percent sales cost products sold due favorable mix well cost improvement initiatives also decrease percent sales selling marketing administrative expenses due companys focus managing expenses partially offset increase investment spending across number businesses focused driving future growth table contents research development research development activities represent significant part companys business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumers patients worldwide costs research activities excluding inprocess research development charges follows dollars millions research development expense percent increase prior year percent sales research development expense percent sales pharmaceutical segment combined research development expense percent sales consumer medical devices diagnostics segments respectively research development activities accelerated pharmaceutical segment increasing billion compound annual growth rate approximately fiveyear period since increased investment research development segments demonstrates companys focus knowledge based products reflects significant number projects late stage development inprocess research development company recorded inprocess research development iprd charges million tax related acquisitions consumer healthcare business pfizer inc vascular control systems inc ensure medical inc colbar lifescience ltd hand innovations llc future medical systems sa consumer healthcare business pfizer inc accounted million tax iprd charges included operating profit consumer segment iprd charges following acquisitions included operating profit medical devices diagnostics segment vascular control systems inc privately held company focused developing medical devices treat fibroids control bleeding obstetric gynecologic applications accounted million tax iprd charges ensure medical inc privately held company develops devices postcatheterization closure femoral artery accounted million tax iprd charges colbar lifescience ltd privately held company specializing reconstructive medicine tissue engineering accounted million tax iprd charges hand innovations llc privately held manufacturer fracture fixation products upper extremities accounted million tax iprd charges future medical systems sa privately held company primarily develops manufactures markets arthroscopic fluid management systems accounted million tax iprd charges company recorded iprd charges million tax related acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial rights certain patents knowhow field sedation analgesia scott lab inc transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules accounted million tax iprd charges included operating profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgicals market accounted million tax iprd charges included operating profit medical devices diagnostics segment peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections accounted million tax iprd charges included operating profit pharmaceutical segment million tax iprd charge related scott lab inc referred included operating profit medical devices diagnostics segment company recorded iprd charges million tax result acquisition us commercial rights certain patents knowhow field sedation analgesia scott lab inc charge included operating profit medical devices diagnostics segment income expense net income expense net includes gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses disposal property plant equipment currency gains losses minority interests litigation settlements liabilities royalty income change income expense net increase income millionin income expense net included gain associated guidant acquisition agreement termination fee less associated expenses million income expense net also included royalty income partially offset expenses associated recording additional product liability reserves integration costs associated acquisition pfizer consumer healthcare income expense net included royalty income partially offset several expense items none individually significant income expense net included several expense items none individually significant partially offset royalty income operating profit segment operating profits segment business follows percent segment sales dollars millions consumer pharmaceutical med devices diag segments total less incomeexpenses allocated segments earnings provision taxes income amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense table contents graph consumer segment consumer segment operating profit decreased percent sales operating profit declined resulting million iprd expenses well expenses associated pfizer consumer healthcare integration recorded consumer segment operating profit increased prior year percent sales operating profit increased slightly despite increases investment spending advertising research development pharmaceutical segment pharmaceutical segment operating profit increased percent sales increased increase result million iprd recorded partially offset increases research development spending lower gross margins pharmaceutical segment operating profit decreased percent sales declined change primarily due increased investment research development spending well impact million iprd expenses medical devices diagnostics segment operating profit medical devices diagnostics segment increased percent sales increased primary driver improved operating profit guidant acquisition agreement termination fee less associated expenses million recorded partially offset increases iprd charges addition advertising promotional expense leveraging offset part increases research development spending medical devices diagnostics segment operating profit increased percent sales increased increase driven improved gross margins due cost reduction programs product mix primarily related cypher sirolimuseluting stent partially offset increased investment research development spending interest income expense interest income increased million due primarily higher rates interest well higher average cash balance despite billion common stock repurchase program increase acquisition activity cash balance including current marketable securities billion end averaged billion compared billion average cash balance interest expense increased slightly compared due higher average debt balance billion billion partially offset decrease interest rates interest income increased million due primarily higher rates interest well higher average cash balance cash balance including current marketable securities billion end averaged billion compared billion average cash balance interest expense decreased compared due part decrease average debt balance billion billion provision taxes income worldwide effective income tax rate tax rate benefited reversal tax allowances million associated tibotec business partially offset guidant acquisition agreement termination fee recorded rate effective tax rate included benefit million due reversal tax liability previously recorded fiscal fourth quarter related technical correction american jobs creation act liquidity capital resources cash flows cash flow operations billion increase billion increase cash generated operations result net income increase billion net non cash impact iprd charges major changes assets liabilities billion increase accounts payable accrued liabilities partially offset billion increase deferred taxes billion increase current noncurrent assets net cash used investing activities increased billion primarily due billion increase acquisition activity occurred late fiscal fourth quarter detailed discussion mergers acquisitions see note also billion net decrease sales investments capital expenditures billion billion billion respectivelynet cash used financing activities increased billion due billion used common stock repurchase program publicly announced march completed early fiscal fourth quarter partially offset billion net proceeds short term debt cash current marketable securities billion end compared billion end primarily due acquisition consumer healthcare business pfizer inc december cash generated operations amounted billion billion cash generated operations billion major factors contributing increase net income increase billion net noncash impact iprd charges billion decrease current noncurrent assets also contributed increase partially offset billion decrease accounts payable accrued liabilities additionally cash payments approximately billion made previously accrued taxes repatriation undistributed international earnings accordance american jobs creation act also increase approximately billion pension funding compared table contents graph financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency products costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote total unused credit available company approximates billion including billion credit commitments billion expire september billion expire october billion expire september also included billion uncommitted lines various banks worldwide expire total borrowings end billion billion respectively increase borrowings result financing acquisition consumer healthcare business pfizer inc december net debt cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend increase period ended december material cash commitments johnson johnson continues one industrial companies triple credit rating summary borrowings found note longterm contractual obligations commitments company longterm contractual obligations primarily lease debt obligations unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities december see notes details longterm unfunded operating debt retirement leases obligations plans total dollars millions total amounts include interest expense share repurchase dividends march company announced board directors approved stock repurchase program authorizing company buy back billion companys common stock program completed early fiscal fourth quarter million shares repurchased addition company annual program repurchase shares use employee stock incentive plans company increased dividend th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends table contents information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal self insurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs derived estimating sales volumes incentive period recorded products sold reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business years ended december january consumer segment balance balance beginning payments end period accruals period dollars millions accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset pharmaceutical segment balance balance beginning payments end period accruals period dollars millions accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset includes million related previously estimated performancebased rebate allowances managed care contracts table contents medical devices diagnostics segment balance balance beginning payments end period accruals period dollars millions accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting us tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future management believes changes estimates would result material effect companys results operations cash flows financial position company repatriated billion undistributed international earnings accordance american jobs creation act ajca recorded tax charge million fiscal fourth quarter fiscal second quarter company recorded tax benefit million due reversal tax liability previously recorded fiscal fourth quarter associated technical correction made ajca may december january cumulative amount undistributed international earnings wereapproximately billion billion respectively company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based managements judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts third party insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected third party insurers longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect rate change would companys results operations company adopted sfas employers accounting defined pension postretirement plans amendment fasb statements r statement requires recognition funded status benefit plan statement financial position changes funded status year changes occur recognized comprehensive income oci net tax stock options fiscal first quarter company adopted sfas r share based payment company applied modified retrospective transition method implement sfas r previously reported financial statements restated accordance provisions sfas r see note information regarding stock options new accounting standards december financial accounting standards board fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options restricted stock units statement requires measurement cost employee services received exchange award equity instruments employee stock options restricted stock units fair value grant date cost recognized period employee required provide services exchange award requisite service period company adopted statement fiscal first quarter applying modified retrospective transition method previously reported financial statements restated reflect adoption sfas r table contents company implemented sfas inventory costs amendment arb fiscal first quarter adoption statement material effect companys results operations cash flows financial position june fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return interpretation also provides guidance derecognition classification matters fin effective fiscal year company adopt accordingly company assessing impact adoption fin currently believe adoption material effect results operations cash flows financial position september fasb issued statement financial accounting standards fair value measurements statement defines fair value establishes framework measuring fair value generally accepted accounting principles expands disclosures fair value measurements statement effective fiscal first quarter company adopt statement time company believes adoption sfas material effect results operations cash flows financial position september fasb issued statement financial accounting standards employers accounting defined pension postretirement plans amendment fasb statements r statement requires recognition funded status benefit plan statement financial position also requires recognition component comprehensive income oci net tax gains losses prior service costs credits arise period recognized components net periodic benefit cost pursuant statements statement also new provisions regarding measurement date well certain disclosure requirements statement effective fiscal year end company adopted statement time september sec issued staff accounting bulletin sab expresses staffs views regarding process quantifying financial statement misstatements bulletin effective fiscal year end implementation bulletin impact companys results operations cash flows financial position following accounting pronouncements became effective material impact companys results operations cash flows financial position fin accounting conditional asset retirement obligations interpretation fasb statement sfas exchanges nonmonetary assets amendment apb following accounting pronouncements became effective material impact companys results operations cash flows financial position eitf issue whether investor apply equity method accounting investments common stock eitf issue accounting preexisting relationships parties business combination economic market factors johnson johnson aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns johnson johnson long standing policy pricing products responsibly period united states weighted average compound annual growth rate johnson johnson net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company faces various worldwide health care changes may result pricing pressures include health care cost containment government legislation relating sales promotions reimbursementthe company also operates environment become increasingly hostile intellectual property rights generic drug firms filed abbreviated new drug applications seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged abbreviated new drug application filings generic firms introduce generic versions product issue resulting potential substantial market share revenue losses product information see discussion litigation filers abbreviated new drug applications note legal proceedings company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued companys balance sheet selfinsurance program third party product liability insurance company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued companys balance sheet expected material adverse effect companys financial position although resolution reporting period one matters could significant impact companys results operations cash flows period see note information regarding legal proceedings table contents common stock market prices companys common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements company undertake update forwardlooking statements result new information future events developments risks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents us foreign health care reforms governmental laws regulations trends toward health care cost containment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action companys report year ended december includes exhibit discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act table contents johnson johnson subsidiaries consolidated balance sheets december january dollars millions except share per share data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes goodwill net notes deferred taxes income note assets note total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements table contents johnson johnson subsidiaries consolidated statements earnings dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes see notes consolidated financial statements table contents johnson johnson subsidiaries consolidated statements equity dollars millions note note receivable employee accumulated stock common treasury comprehensive retained ownership plan comprehensive stock issued stock total income earnings esop income amount amount balance december net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december see notes consolidated financial statements table contents johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles stock based compensation purchased inprocess research development deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions increase accounts receivable increasedecrease inventories increasedecrease accounts payable accrued liabilities increasedecrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions see notes consolidated financial statements table contents notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby kids care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal anti infective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology areas products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses new accounting pronouncements december fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options restricted stock units statement requires measurement cost employee services received exchange award equity instruments employee stock options restricted stock units fair value grant date cost recognized period employee required provide services exchange award requisite service period company adopted statement fiscal first quarter applying modified retrospective transition method previously reported financial statements restated reflect adoption sfas r see note company implemented sfas inventory costs amendment arb fiscal first quarter adoption statement material effect companys results operations cash flows financial position june fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return interpretation also provides guidance derecognition classification matters fin effective fiscal year company adopt accordingly company assessing impact adoption fin currently believe adoption material effect results operations cash flows financial position september fasb issued statement financial accounting standards fair value measurements statement defines fair value establishes framework measuring fair value generally accepted accounting principles expands disclosures fair value measurements statement effective fiscal first quarter company adopt statement time company believes adoption sfas material effect results operations cash flows financial positionin september fasb issued statement financial accounting standards employers accounting defined pension postretirement plans amendment fasb statements r statement requires recognition funded status benefit plan statement financial position also requires recognition component comprehensive income oci net tax gains losses prior service costs credits arise period recognized components net periodic benefit cost pursuant statements statement also new provisions regarding measurement date well certain disclosure requirements statement effective fiscal year end company adopted statement time see note september sec issued staff accounting bulletin sab expresses staffs views regarding process quantifying financial statement misstatements bulletin effective fiscal year end implementation bulletin impact companys results operations cash flows financial position following accounting pronouncements became effective material impact companys results operations cash flows financial position fin accounting conditional asset retirement obligations interpretation fasb statement sfas exchanges nonmonetary assets amendment apb table contents following accounting pronouncements became effective material impact companys results operations cash flows financial position eitf issue whether investor apply equity method accounting investments common stock eitf issue accounting preexisting relationships parties business combination cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlived assets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated informationsales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method goodwill intangible assets effective beginning fiscal year accordance sfas company discontinued amortization relating existing goodwill indefinite lived intangible assets nonamortizable sfas requires goodwill nonamortizable intangible assets assessed annually impairment company completed annual impairment test fiscal fourth quarter impairment determined future impairment tests performed annually fiscal fourth quarter sooner triggering event occurs intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets financial instruments company follows provisions sfas accounting derivative instruments hedging activities amended sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction table contents company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction fair value derivative instrument ie forward foreign exchange contract currency swap aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings insignificant company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available result cost availability factors effective november company ceased purchasing third party product liability insurance based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation december january cumulative amount undistributed international earnings approximately billion billion respectivelydeferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations instance determining annual pension postemployment benefit costs company estimates rate return plan assets cost future health care benefits actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case inventories end inventories comprised dollars millions raw materials supplies goods process finished goods table contents property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december total dollars millions commitments capital leases significant employee related obligationsat end employee related obligations dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation less current benefits payable employee related obligations prepaid employee related obligations million million respectively included assets consolidated balance sheet prepaid employee related obligations decreased significantly due implementation sfas borrowings components longterm debt follows effective effective rate rate dollars millions zero coupon convertible subordinated debentures due debentures due debentures due notes due debentures due notes due industrial revenue bonds less current portion weighted average effective rate company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments billion expire september billion expire october billion expire september also included billion uncommitted lines various banks worldwidethat expire interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material company filed shelf registration us securities exchange commission sec became effective november enables company issue billion debt securities warrants purchase debt securities debt issued full amount remained available december july alza completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity december outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately million shares issued december due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue table contents price plus accreted original issue discount december january fair value based quoted market value debentures million million respectively shortterm borrowings current portion long term debt amounted billion end billion raised commercial paper program remainder represents principally local borrowing international subsidiaries aggregate maturities longterm obligations commencing dollars millions certain business relationships member companys board directors chief executive officer major bank bank provided services company including providing line credit payments made significant either company bank intangible assets goodwill end gross net amounts intangible assets goodwill dollars millions trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net subtotal intangible assets gross less accumulated amortization subtotal intangible assets net goodwill gross less accumulated amortization goodwill net total intangible assets goodwill gross less accumulated amortization total intangible assets goodwill net goodwill december january allocated segment business follows med dev consumer pharm diag total dollars millions goodwill january acquisitions translationother goodwill january acquisitions translationother goodwill december weighted average amortization periods patents trademarks intangible assets years years respectively amortization expense amortizable intangible assets fiscal years ended december january january million million million tax respectively certain patents intangibles written fair value fiscal years resulting charge included amortization expense estimated amortization expense five succeeding years approximates million tax per year substantially amortization expense included cost products sold income taxes provision taxes income consists dollars millions currently payable us taxes international taxes deferred us taxes international taxes table contents comparison income tax expense federal statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates statutory puerto rico ireland operations research orphan drug tax credits us state local international subsidiaries excluding ireland repatriation international earnings iprd effective tax rate company subsidiaries operating puerto rico various tax incentive grants also us possessions tax credit expired applies certain operations puerto rico addition company subsidiaries manufacturing ireland incentive tax rate increase tax rate mainly due reversal tax liability million reported tax provision resulted technical correction american jobs creation act partially offset benefit reported reversal tax allowances million associated tibotec business temporary differences carry forwards follows deferred tax deferred tax asset liability asset liability dollars millions employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangibles miscellaneous us total deferred income taxes difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included income expense losses million million million respectively common stock stock option plans stock compensation agreements stock options december company stockbased compensation plans shares outstanding contracts companys stock option plans longterm incentive plan stock compensation plan nonemployee directors plan centocor innovasive devices alza inverness scios stock option plans options restricted stock granted plans except longterm incentive plan compensation cost recorded sfas r charged income plans million million million total income tax benefit recognized income statement share based compensation costs million million million share based compensation costs capitalized part inventory insignificant periods stock options expire years date grant vest service periods range six months five years options granted current market price date grant longterm incentive plan company may issue million shares common stock shares available future grants longterm incentive plan million end company settles employee stock option exercises treasury shares treasury shares replenished throughout year number shares used settle employee stock option exercises table contents fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table starting expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthe money traded johnson johnson options life years prior expected volatility based year weekly historical volatility rate historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted fair value estimated based weighted average assumptions riskfree rate expected volatility expected life yrs yrs yrs dividend yield summary option activity plan december january january changes years ending dates presented weighted aggregate outstanding average intrinsic shares exercise price value shares thousands shares december options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million respectively total unrecognized compensation cost million december million january million january weighted average period cost recognized years years years following table summarizes stock options outstanding exercisable december outstanding exercisable average average average exercise exercise exercise price range options life price options price shares thousands average contractual life remaining years stock options exercisable january january average price average life years options average price average life years respectively restricted stock units company grants restricted stock units vesting period three years company settles employee stock issuance treasury shares treasury shares replenished throughout year number shares used employee stock issuances summary stock activity plan december outstanding shares shares thousands shares january stock granted stock issued stock canceledforfeited shares december average fair value restricted stock units granted using fair market value date grant fair value restricted stock units discounted dividends paid restricted stock units vesting period fair value shares issued million table contents segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics segments total less income expenses allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales intersegment sales significant company customer represented total revenues sales top distributors accounted total revenues amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense general corporate includes cash marketable securities includes million million inprocess research development iprd consumer medical devices diagnostics segments respectively medical devices diagnostics segment also includes guidant acquisition agreement termination fee less associated expenses million includes million million iprd pharmaceutical medical devices diagnostics segments respectively includes million iprd medical devices diagnostics segment longlived assets include property plant equipment net respectively intangible assets net respectively table contents accumulated comprehensive income components comprehensive incomeloss consist following total unrealized gains accumulated foreign gains losses currency losses employee derivatives comprehensive translation securities benefit plans hedges incomeloss dollars millions dec changes net change due hedging transactions net amount reclassed net earnings net changes jan changes net change due hedging transactions net amount reclassed net earnings net changes jan changes net change due hedging transactions net amount reclassed net earnings net changes dec total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million tax effect unrealized gainslosses equity securities balance expense million million million respectively tax effect related employee benefit plans million million tax effect gainslosses derivatives hedges losses million million benefit million see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments international subsidiaries pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care insurance us retired employees dependents many international employees covered governmentsponsored programs direct cost company significant retirement plan benefits primarily based employees compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements december january respectively measurement date us international retirement benefit plans september fasb issued statement financial accounting standards employers accounting defined benefit pension postretirement plans amendment fasb statements r requires employer fully recognize overfunded underfunded status pension postretirement benefit plans asset liability financial statements addition company required recognize component comprehensive income loss actuarial gains losses prior service costs credits arise period immediately recognized components net periodic benefit cost incremental effect applying sfas billion reduction shareholders equity net deferred taxes table contents net periodic benefit cost companys defined benefit retirement plans benefit plans included following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements net periodic benefit cost net periodic benefit cost attributable us retirement plans million million million amounts expected recognized net periodic cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net actuarial loss amortization prior service cost amortization net transition obligation weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year retirement plans benefit plans dollars millions us benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities expected longterm rate return plan assets assumptions determined using building block approach considering historical averages real returns asset class certain countries historical returns meaningful consideration given local market expectations longterm returns following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage point increase point decrease dollars millions health care plans total interest service cost postretirement benefit obligation table contents following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service costs interest costs plan participant contributions amendments actuarial gainslosses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions divestitures acquisitions curtailments settlements benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year unrecognized actuarial losses unrecognized prior service costs unrecognized net transition assets total recognized consolidated balance sheet amounts recognized companys balance sheet consist following adoption sfas book accruals prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet adoption sfas noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet net actuarial losses prior service costscredits unrecognized net transition assets total tax effects change accumulated comprehensive income due adoption sfas tax effects accumulated benefit obligations end year includes post employment benefits per adoption sfas table contents strategic asset allocations determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status companys plans considered nonmature plans longterm strategic asset allocations consistent types plans emphasis placed diversifying equities broad basis combined currency matching fixed income assets following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans gross medicare rebates benefit plans net company required fund us retirement plans required anticipate funding meet minimum statutory funding requirements international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded following table displays projected future minimum contributions companys us international unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans companys retirement plan asset allocation december january target allocations follows percent plan assets target allocation us retirement plans equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets companys benefit plans unfunded except us life insurance contract assets million million december january respectively fair value johnson johnson common stock directly held plan assets million total plan assets million total plan assets december january respectively plans accumulated benefit obligations excess plan assets consist following retirement plans dollars millions accumulated benefit obligation projected benefit obligation plan assets fair value table contents cash cash equivalents marketable securities december january amortized unrealized estimated amortized unrealized estimated cost gainslosses fair value cost gainslosses fair value dollars millions current investments cash government securities obligations corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities noncurrent investments marketable securities financial instruments company follows provisions sfas requiring derivative instruments recorded balance sheet fair value december balance deferred net gains derivatives included accumulated comprehensive income million aftertax company expects substantially amount reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative derivative gainslosses initially reported component comprehensive income reclassified earnings period forecasted transaction affects earnings years ended december january january net impact hedge ineffectiveness transactions qualifying hedge accounting discontinuance hedges companys financial statements insignificant refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world high quality money market instruments company policy making investments commercial institutions least equivalent credit rating average investments mature within six months company incurred related losses savings planthe company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop unless employee chose redirect investment establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareholders equity remaining shares held esop trust allocated participant accounts end february march going forward company match made cash follows individual employees investment elections total company contributions plans million million million table contents mergers acquisitions divestitures certain businesses acquired billion cash billion liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisitions except noted december company completed acquisition consumer healthcare business pfizer inc purchase price billion cash operating results consumer healthcare business pfizer inc reported companys financial statements beginning results subsequent acquisition date significant order obtain regulatory approval transaction company agreed divest certain overlapping businesses company completed divestiture zantac product december divestitures kaopectate unisom cortizone balmex act products january following table provides pro forma results operations fiscal year ended january fiscal year ended december consumer healthcare business pfizer inc acquired beginning period presented pro forma results include effect divestitures certain purchase accounting adjustments estimated changes depreciation amortization expense acquired tangible intangible assets however pro forma results include anticipated cost savings effects planned integration consumer healthcare business pfizer inc accordingly amounts necessarily indicative results acquisition occurred dates indicated may occur future pro forma results year ended year ended december january dollars millions except per share data net sales net earnings diluted net earnings per common share company process finalizing allocation purchase price individual assets acquired liabilities assumed preliminary allocation purchase price included current period balance sheet based best estimates management completion purchase price allocation may result adjustments carrying value consumer healthcare business pfizer incs recorded assets liabilities revisions useful lives intangible assets determination residual amount allocated goodwill related depreciation amortization acquired assets also subject revision based final allocation following table presents preliminary allocation purchase price related consumer healthcare business pfizer inc date acquisition dollars millions current assets property plant equipment goodwill intangible assets total assets acquired current liabilities noncurrent liabilities total liabilities assumed net assets acquired acquisition consumer healthcare business pfizer inc resulted billion goodwill allocated consumer segment preliminary purchase price allocation identifiable intangible assets included current period balance sheet follows dollars millions intangible assets determinable lives brands patents technology customer relationships total amortizable intangibles brands indefinite lives total intangible assets weighted average life million total amortizable intangibles approximately years majority intangible asset valuation relates brands assessment brands indefinite life determinable life based number factors including competitive environment market share brand history product life cycles operating plan macroeconomic environment countries brands sold indefinitelife brands account total value indefinitelife brands include listerine nicorette neosporin sudafed benadryl visine benylin determinablelife brands include purell actifed efferdent regional country specific brands determinablelife brands asset lives ranging years patents technology intangibles concentrated upper respiratory oral care medicated skin care tobacco dependence hair growth businesses asset lives ranging years estimated customer relationship intangible asset useful lives ranging years reflect low historical projected customer attrition rates among consumer healthcare business pfizer incs major retailer distributor customers iprd charge related acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associated rights obtained pending switch zyrtec us prescription counter status table contents value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent regulatory risk discount rate applied company process completing analysis integration plans pursuant company incur costs primarily related elimination certain duplicate selling general administrative functions two companies areas global business services corporate staff gotomarket support well excess manufacturing capacity addition acquisition consumer healthcare business pfizer inc acquisitions included animas corporation leading maker insulin infusion pumps related products hand innovations llc privately held manufacturer fracture fixation products upper extremities future medical systems sa privately held company primarily develops manufactures markets arthroscopic fluid management systems vascular control systems inc privately held company focused developing medical devices treat fibroids control bleeding obstetric gynecologic applications groupe vendme sa privately held french marketer adult baby skin care products colbar lifescience ltd privately held company specializing reconstructive medicine tissue engineering ensure medical inc privately held company develops devices postcatheterization closure femoral artery excluding acquisition consumer healthcare business pfizer inc excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd primarily associated acquisitions hand innovations llc future medical systems sa vascular control systems inc colbar lifescience ltd ensure medical inc iprd charge related acquisition hand innovations llc million associated fracture repair technologies value iprd calculated using cash flow projections discounted risk inherent projects probability success factor ranging used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition future medical systems sa million associated nextra duo pump product technologies value iprd calculated using cash flow projections discounted risk inherent projects probability success factor technologies used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition vascular control systems inc million associated flostat system technology value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition colbar lifescience ltd million associated evolence family products biodegradable dermal fillers value iprd calculated using cash flow projections discounted risk inherent projects probability success factor ranging used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition ensure medical inc million associated femoral artery closure device value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisitions acquisitions included transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules closure medical corporation company expertise intellectual property biosurgicals market peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections rights consumer professionally dispensed rembrandt brand oral care products whitening toothpastes strips systems mouth rinses excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd primarily associated acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals incthe iprd charge related acquisition transform pharmaceuticals inc million associated research related discovery application superior formulations value iprd calculated using cash flow projections discounted risk inherent projects discount rate applied iprd charge related acquisition closure medical corporation million associated omnextm surgical sealant vascular indications outside europe potential indications worldwide value iprd calculated using cash flow projections discounted risk inherent projects probability success factor vascular indications indications used reflect inherent clinical regulatory risk discount rate applied vascular indications iprd charge related acquisition peninsula pharmaceuticals inc million associated development doripenem phase iii clinical trials value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied remaining million iprd associated acquisition international commercial rights certain patents knowhow field sedation analgesia scott lab inc value iprd calculated using cash flow table contents projections discounted risk inherent projects discount rate certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition addition per terms acquisition agreement link spine group inc million cash paid owners link spine group inc based date us food drug administration fda approved charittm artificial disc thus total cash expenditures related acquisitions million acquisitions included mercks interest johnson johnsonmerck consumer pharmaceuticals co european nonprescription pharmaceutical joint venture including infrastructure brand assets managed european joint venture egea biosciences inc exercise option acquire remaining outstanding stock owned johnson johnson developed proprietary technology platform called gene writer allows rapid highly accurate synthesis dna sequences gene assembly construction large synthetic gene libraries artemis medical inc privately held company ultrasound xray visible biopsy site breast markers well hybrid markers us commercial rights certain patents knowhow field sedation analgesia scott lab inc biapharm sas privately held french producer marketer skin care products centered around leading brand biafine assets micomed privately owned manufacturer spinal implants primarily focused supplying german market acquisition ambi skin care brand women color excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill million related us fda approval charittm artificial disc recorded additional goodwill associated link spine group inc acquisition thus total additions intangibles goodwill million approximately million identified value iprd associated scott lab acquisition value iprd calculated using cash flow projections discounted risk inherent projects discount rate supplemental pro forma information per sfas business combinations sfas goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position divestitures material effect companys results operations cash flows financial position legal proceedings product liability company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued companys balance sheet available thirdparty product liability insurance multiple products johnson johnson subsidiaries subject numerous product liability claims lawsuits including ortho evra risperdal duragesic charittm artificial disc december approximately claimants filed lawsuits made claims regarding injuries allegedly due ortho evra claimants respect risperdal respect duragesic respect charittm claimants seek substantial compensatory available punitive damages numerous claims lawsuits united states relating drug propulsid withdrawn general sale companys janssen pharmaceutica inc subsidiary resolved currently enrolled settlement programs aggregate cap million payments company litigation concerning propulsid pending canada class action persons alleging adverse reactions drug recently certified johnson johnson subsidiaries responsible marketing products vigorously defending claims except settlement deemed appropriate affirmative stent patent litigationin patent infringement actions tried delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic based number cordis vascular stent patents december jury damage action boston scientific returned verdict million jury medtronic action returned verdict million multiple posttrial proceedings appeals ensued respect verdicts ultimate outcome still subject uncertainty cordis also arbitration claim medtronic accusing medtronic infringement sale stent products introduced medtronic subsequent products subject earlier action referenced subsequent products found licensed medtronic pursuant license arbitration panel march arbitration proceedings determine whether royalties owed products january cordis filed patent infringement action boston scientific delaware federal district court accusing expresstm taxus liberte stents infringing palmaz patent expired november liberte stent also accused infringing cordis gray patent expires june jury found expresstm taxus liberte stents infringed palmaz patent liberte stent also infringed gray patent motions filed boston scientific seeking vacate verdict obtain new trial denied june cordis expects boston scientific appeal us court appeals federal circuit patent litigation various johnson johnson subsidiaries products various johnson johnson subsidiaries subject various patent lawsuits outcomes table contents could potentially adversely affect ability subsidiaries sell products require payment past damages future royalties respect matters johnson johnson subsidiary involved vigorously defending claims infringement disputing appropriate validity enforceability patent claims asserted july jury federal district court delaware found cordis cypher stent infringed boston scientifics ding patent cordis cypher bx velocity stents also infringed boston scientifics jang patent jury also found patents valid boston scientific seeks substantial damages injunction action june district court denied motions cordis overturn jury verdicts grant new trial cordis moved reconsideration decisions reconsideration denied cordis appeal court appeals federal circuit district court indicated consider damages willfulness injunctive relief appeals decided trial boston scientifics case asserting infringement cypher stent boston scientifics grainger patent scheduled march adjourned pending decision cordis motion summary judgment case well boston scientific seeks injunction substantial damages boston scientific brought actions belgium netherlands kastenhofer patent enjoin manufacture sale allegedly infringing catheters countries recover damages belgian case pending hearing date set decision lower court netherlands boston scientifics favor appeal germany boston scientific several actions based ding patents pending cordis cypher stent cordis successful actions trial level boston scientific appealed following chart summarizes various patent lawsuits concerning products johnson johnson subsidiaries yet proceed trial plaintiff jj product company patents patent holder court trial date date filed catheters stent delivery systems cordis fitzmaurice medtronic ave ed tex drug eluting stents cordis grainger boston scientific corp del drug eluting stents cordis ding boston scientific corp germany twolayer catheters cordis kasten hofer boston scientific corp nd cal belgium forman stents cordis israel medinol multiple eu jurisdictions contact lenses vision care nicolson ciba vision md fla trial date established litigation filers abbreviated new drug applications andas following chart indicates lawsuits pending generic firms filed abbreviated new drug applications seeking market generic forms products sold various subsidiaries company prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiary company involved successful actions statutory month stay expires ruling district court obtained firms involved ability upon fda approval introduce generic versions product issue resulting substantial market share revenue losses product companys subsidiary noted following chart month stays expired expire respect anda challenges regarding various productspatentnda generic trial date month brand name product holder challenger court date filed stay expires aciphex mg delay release tablet eisai janssen teva dr reddys sd ny mylan sd ny sd ny axert mg almirall teva sd ny orthomcneil neurologics concerta mg controlled release tablet mcneilppc alza andrx del none table contents patentnda generic trial date month brand name product holder challenger court date filed stay expires ditropan xl mg controlled release tablet orthomcneil mylan wv alza impax nd cal ortho tricyclen lo mg mg mg mg orthomcneil barr nj mg mg pepcid complete mcneilppc perrigo sd ny razadynetm janssen teva del mylan del dr reddys del purepac del barr del par del alphapharm del razadynetm er janssen barr nj risperdal tablets mg tablets janssen mylan dr reddys nj apotex nj nj risperdal mtab mg janssen dr reddys nj risperdal oral solution mgml janssen apotex nj topamax mg tablet orthomcneil mylan cobalt nj nj topamax sprinkle mg capsule orthomcneil cobalt mylan nj nj trial date established action mylan dr reddys laboratories regarding risperdal risperidone tablets mtabs district court new jersey ruled october risperdal patent valid enforceable infringed generic products issue entered injunction prohibiting mylan dr reddys marketing generic risperidone products date earlier patent expiration december mylan appealed ruling action mylan respect patent topamax district court new jersey october granted companys subsidiary orthomcneil pharmaceutical incs ortho mcneil motion preliminary injunction barring launch mylan generic version topamax february district court granted orthomcneils motion summary judgment dismissing mylans claim patent obvious remaining issue case company expects judgment case shortly entered orthomcneil mylan appeal action mylan involving orthomcneils product ditropan xl oxybutynin chloride court september found ditropan xl patent invalid infringed mylans generic product rulings affirmed court appeals federal circuit september mylan impax received final fda approval launched products november weeks following adverse ruling ditropan xl anda litigation mylan september johnson johnson alza received seven antitrust class action complaints filed purchasers product allege johnson johnson alza violated antitrust laws various states knowingly pursuing baseless patent litigation thereby delaying entry market mylan impaxtable contents action impax involving anda referencing mcneilppcs product concerta mcneil alza corporation subsidiaries company dismissed prejudice claim infringement impax respect anda respect matters johnson johnson subsidiary involved vigorously defending validity enforceability asserting infringement licensors patents average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl federal district court boston massachusetts plaintiffs cases include classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp mdl proceeding boston plaintiffs moved class certification portion claims august trial judge certified massachusettsonly classes private insurers providing medigap insurance coverage private payers physicianadministered drugs payments based awp judge also allowed plaintiffs file new complaint seeking name proper parties represent national class individuals made copayments physicianadministered drugs covered medicare court appeals declined allow appeal issues january court certified national class noted trial two massachusettsonly class actions concluded massachusetts district court december decision expected first quarter trial judge scheduled jury trials begin april national class action behalf individuals paid copayments medicare part b drugs trial action brought attorney general state alabama making allegations related awp set november additional awp cases brought various attorney generals expected set trial july centocor corporation received request voluntarily provide documents information criminal division us attorneys office district new jersey connection investigation various centocor marketing practices subsequent requests documents received us attorneys office company centocor responded process responding requests documents information december orthomcneil received subpoena us attorneys office boston massachusetts seeking documents relating marketing including alleged offlabel marketing drug topamax topiramate additional subpoena documents served june orthomcneil cooperating responding subpoenas october us attorneys office boston asked attorneys orthomcneil cooperate facilitating subpoenaed testimony several present former orthomcneil employees federal grand jury boston cooperation securing testimony additional witnesses grand jury requested provided january janssen received subpoena office inspector general us office personnel management seeking documents concerning sales marketing payments physicians connection sales marketing clinical trials risperdal risperidone documents subsequent also requested additional subpoena seeking information marketing adverse reactions risperdal received us attorneys office eastern district pennsylvania november janssen cooperating responding subpoenas april several companys pharmaceutical companies requested submit information us senate finance committee use nominal pricing exception calculating best price medicaid rebate program request sent manufacturers top twenty drugs reimbursed medicaid program companys pharmaceutical companies responded request february request supplemental information received senate finance committee responded companys pharmaceutical companies august johnson johnson health care systems inc hcs johnson johnson subsidiary received subpoena dallas texas us attorneys office seeking documents relating relationships group purchasing organization novation hcs johnson johnson subsidiaries companys subsidiaries involved responded subpoena september ortho biotech inc ortho biotech received subpoena us office inspector generals denver colorado field office seeking documents directed sales marketing procrit epoetin alfa present well dealings us oncology inc healthcare services network oncologists ortho biotech responded subpoenatable contents march depuy orthopaedics inc depuy johnson johnson subsidiary received subpoena us attorneys office district new jersey seeking records concerning contractual relationships depuy orthopaedics surgeons surgeonsintraining involved hip knee replacement reconstructive surgery leading orthopaedic companies known received similar subpoena depuy orthopaedics responding subpoena well followon subpoena documents number employees depuy subpoenaed testify grand jury connection investigation june us senate committee finance requested company produce information regarding use several pharmaceutical subsidiaries educational grants similar request sent major pharmaceutical companies july committee specifically requested information educational grants connection drug propulsid follow request received committee additional information january july scios inc scios johnson johnson subsidiary received subpoena us attorneys office district massachusetts seeking documents related sales marketing natrecor scios responding subpoena early august scios advised investigation would handled us attorneys office northern district california san francisco september johnson johnson received subpoena us attorneys office district massachusetts seeking documents related sales marketing eight drugs omnicare inc manager pharmaceutical benefits longterm care facilities johnson johnson subsidiaries involved responding subpoena several employees companys pharmaceutical subsidiaries subpoenaed testify grand jury connection investigation january janssen received civil investigative demand texas attorney general seeking broad categories documents related sales marketing risperdal janssen responding request october texas attorney general joined qui tam action filed janssen texas state court alleging label marketing risperdal seeking compensation alleged adverse reactions due risperdal february johnson johnson received subpoena us securities exchange commission sec requesting documents relating participation several johnson johnson subsidiaries united nations iraq oil food program subsidiaries cooperating sec producing responsive documents june depuy received subpoena us department justice antitrust division requesting documents related manufacture marketing sale orthopaedic devices search warrants executed connection investigation depuy responding request documents wake publicity subpoena depuy served five civil antitrust class actions september janssen received subpoena attorney general state california seeking documents regarding sales marketing sideeffects risperdal well interactions state officials regarding states formulary medicaidreimbursed drugs janssen process responding subpoena november centocor received subpoena seeking documents connection investigation conducted office united states attorney central district california regarding centocors average selling price asp calculations remicade companys contract purchase program centocor producing material responsive subpoena cooperating investigation february johnson johnson voluntarily disclosed us department justice doj us securities exchange commission sec subsidiaries outside united states believed made improper payments connection sale medical devices two smallmarket countries payments may fall within jurisdiction foreign corrupt practices act company provide additional information doj sec cooperate agencies reviews matters september plaintiffs employment discrimination litigation initiated company federal district court new jersey moved certify class african american hispanic salaried employees company affiliates us employed time november present plaintiffs seek monetary damages period present including punitive damages equitable relief court denied plaintiffs class certification motion december plaintiffs sought reconsideration decision company disputes allegations lawsuit vigorously defending themthe company along whollyowned subsidiaries ethicon inc ethicon endosurgery inc hcs defendants federal antitrust action challenging suture endomechanical contracts group purchasing organizations hospitals discounts predicated hospital achieving specified market share targets categories products trial action conmed v johnson johnson et al sdny filed november currently scheduled april conmed alleges damages billion damages would trebled antitrust laws damages liability successfully established trial late december early three purported class actions filed behalf purchasers endomechanical instruments actions filed federal district court central district california november amgen filed suit hoffmannlaroche inc us district court district massachusetts seeking declaration roche product cera roche indicated seek introduce united states infringes number amgen patents concerning epo amgen licenses manufactures epo sale table contents united states companys ortho biotech inc subsidiary nondialysis indications suit preliminary stages october wyeth inc initiated litigation delaware cordis corporation alleging cordis breached license supply agreement pursuant wyeth supplies cordis drug rapamycin used connection cordis cypher sirolimuseluting stent cordis commenced action delaware seeking declaration breach occurred company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued companys balance sheet expected material adverse effect companys financial position although resolution reporting period one matters could significant impact companys results operations cash flows period earnings per share following reconciliation basic net earnings per share diluted net earnings per share years ended december january january shares millions except per share data basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation includes dilutive effect convertible debt decrease interest expense million million million tax years respectively diluted net earnings per share excludes million million million shares underlying stock options respectively exercise price options greater average market value would result antidilutive effect diluted earnings per share capital treasury stock changes treasury stock treasury stock shares amount amounts millionsexcept treasury stock number shares thousands balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december shares common stock issued shares end cash dividends paid per share compared dividends per share per share table contents selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth quarter quarter quarter quarter quarter quarter quarter quarter dollars millions except per share data segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter includes aftertax gain million guidant acquisition termination fee aftertax charge million inprocess research development iprd second quarter includes aftertax charge million iprd third quarter includes aftertax charge million iprd fourth quarter includes aftertax charge million iprd second quarter includes aftertax charge million iprd million tax benefit due reversal tax liability related technical correction associated american jobs creation act fourth quarter includes aftertax charge million iprd shifts sales lower tax jurisdictions expenditures higher tax jurisdictions significant impact fiscal fourth quarters tax rate subsequent eventsduring fiscal first quarter company completed acquisition conor medsystems inc cardiovascular device company billion cash fiscal first quarter accordance regulatory approval acquisition consumer healthcare business pfizer inc company announced closing divestiture kaopectate unisom cortizone balmex act products chattem inc million cash table contents managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting december company completed acquisition consumer healthcare business pfizer inc due close proximity completion date acquisition date managements assessment effectiveness companys internal control financial reporting management excluded consumer healthcare business pfizer inc assessment internal control financial reporting total assets consumer healthcare business pfizer inc primarily intangible assets goodwill represented companys total assets fiscal year ended december operating results consumer healthcare business pfizer inc acquired december reported companys financial statements beginning results subsequent acquisition date significant based companys processes assessment described management concluded december companys internal control financial reporting effective managements assessment effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein table contents report independent registered public accounting firm shareholders board directors johnson johnson completed integrated audits johnson johnsons consolidated financial statements internal control financial reporting december accordance standards public company accounting oversight board united states opinions based audits presented consolidated financial statements opinion accompanying consolidated balance sheets related consolidated statements earnings statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries company december january results operations cash flows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion discussed note due implementation sfas company changed manner accounts pensions benefits december internal control financial reporting also opinion managements assessment included accompanying managements report internal control financial reporting company maintained effective internal control financial reporting december based internal control integrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions managements assessment effectiveness companys internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures consider necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate described managements report internal control financial reporting management excluded consumer healthcare business pfizer inc assessment internal control financial reporting december acquired company december also excluded consumer healthcare business pfizer inc audit internal control financial reporting total assets consumer healthcare business pfizer inc represent related consolidated financial statement amounts december pricewaterhousecoopers llp new york new york february table contents summary operations statistical data dollars millions except per share figures sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands net interest income also included cost materials services category includes taxes income payroll property business taxes table contents shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested performance graph performance graph ex yexvhtm ex subsidiariesexhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown december certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent jurisdiction name subsidiary organization us subsidiaries advanced sterilization products services inc new jersey alza corporation delaware alza land management inc delaware animas corporation delaware babycenter llc delaware biosense webster inc california centocor biologics llc pennsylvania centocor inc pennsylvania centocor research development inc pennsylvania closure medical corporation delaware cna development llc delaware codman shurtleff inc new jersey cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy disc inc delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania gynopharma inc delaware hand innovations llc delawareheartport inc delaware iso holding corp delaware jj holdings nevada inc nevada janssen finance company floridajurisdiction name subsidiary organization janssen inc delaware janssen ortho llc delaware janssen lp new jersey jjhc llc delaware johnson johnson baby products inc delaware johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson pharmaceutical services llc new jersey johnson johnson pharmaceutical trading co inc delaware johnson johnson professional co pr inc delaware johnson johnson regenerative therapeutics llc delaware johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical products corporation delaware lifescan inc california lifescan llc delaware lifescan products llc california mcneil healthcare llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech clinical affairs llc new jersey ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co floridaorthomcneil inc new jersey orthomcneil neurologics inc new jersey orthomcneil pharmaceutical inc delaware rutan realty llc new jerseyjurisdiction name subsidiary organization scios inc delaware teramed corporation delaware therapeutic discovery corporation delaware tylenol company new jersey transform pharmaceuticals inc delaware winthorpe valentine inc delaware international subsidiaries alza ireland limited ireland apsis sas france calisto limited trinidad tobago carlo erba otc srl italy centocor biologics ireland limited ireland centocor bv netherlands cilag advanced technologies gmbh switzerland cilag ag switzerland cilag de mexico de rl de cv mexico cilag gmbh international switzerland cilag holding ag switzerland codman sarl switzerland colbar lifescience ltd israel cordis cashel limited ireland cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy france sas france depuy international limited united kingdom depuy international holdings limited united kingdom depuy ireland limited ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy orthopedie sas france depuy spine sarl switzerland depuy uk holdings limited united kingdom drumbeat limited ireland ethicon gmbh germany ethicon ireland limited ireland ethicon sarl switzerland ethicon sas france ethnor proprietary limited south africa fms future medical system sa switzerland group vendome francehigh wycombe property management limited united kingdom janssen animal health bvba belgium janssencilag ab sweden janssencilag ag switzerlandjurisdiction name subsidiary organization janssencilag bv netherlands janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssenortho inc canada janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc general services cvba belgium jc healthcare ltd israel jhc nederland bv netherlands johnson johnson ab sweden johnson johnson administracao de investimentos ltda brazil johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson comercio e distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer hong kong limited hong kong johnson johnson consumer thailand limited thailand johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited england johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austriajohnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson holding ab swedenjurisdiction name subsidiary organization johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson ireland limited ireland johnson johnson kft hungary johnson johnson k k japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson llc russia johnson johnson management limited england johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty limited australia johnson johnson medical sa argentina johnson johnson medical shanghai ltd china johnson johnson medical spa italy johnson johnson merck consumer pharmaceuticals canada canada johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson produtos profissionais ltda brazil johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty ltd australia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson swiss finance company limited united kingdomjohnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland laboratoires polive snc francejurisdiction name subsidiary organization laboratoires vendome sas france latam international investment company france latam properties holdings ireland lifescan canada ltd canada lifescan scotland limited scotland mcneil ab sweden mcneil denmark aps denmark mcneil esbjerg aps denmark mcneil gmbh co ohg germany mcneil iberica slu spain mcneil pdi inc canada mcneil sas france mcneil sweden ab france medos international sarl switzerland medos sarl switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostics united kingdom orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics nv belgium orthoclinical diagnostics sas france pfizer consumer health products company england pfizer consumer healthcare england pfizer consumer healthcare comm va belgium pfizer consumer healthcare gmbh germany pfizer consumer healthcare ireland ireland pfizer consumer healthcare mexico de rl de cv mexico pfizer consumer healthcare scompa spain pfizer consumer healthcre srl italy pfizer sante grand public france pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloids pty ltd australia tibotec bvba belgium tibotec pharmaceuticals ltd ireland tibotecvirco comm va belgium turnbuckle investment company ireland vania expansion snc france xianjanssen pharmaceutical ltd china recently acquired name change pending ex yexvhtm ex consent independent registered public accounting firmexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form form johnson johnson report dated february relating financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appears annual report shareholders incorporated annual report also consent incorporation reference report dated february relating financial statement schedule appears pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act william c weldon certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report preparedb designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information andb fraud whether material involves management employees significant role companys internal control financial reporting william c weldon william c weldon chief executive officer date february exb yexvwbhtm exb certificationexhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information andb fraud whether material involves management employees significant role companys internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exa yexvwahtm exa certificationexhibit certification chief executive officer pursuant section sarbanesoxley act undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge companys annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company william c weldon william c weldon chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability section exb yexvwbhtm exb certificationexhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge companys annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company dominic j caruso dominic j caruso chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability section ex yexvhtm ex cautionary statementexhibit cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company undertake update forward looking statements result new information future events developments important factors could cause companys actual results differ companys expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors challenges companys patents competitors allegations companys products infringe patents third parties could potentially affect companys competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions interruptions computer communication systems including computer viruses could impair companys ability conduct business communicate internally customers health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting us foreign operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights including particular proposed amendments thehatchwaxman act implementation medicare prescription drug improvement modernization act possible drug reimportation legislation competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important companys success areas business challenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation adverse company including product liability claims patent infringement claims antitrust claims health care industry come increased scrutiny government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including debarment government business product efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda foreign counterparts declining sales impact business combinations including acquisitions divestitures internally company externally pharmaceutical medical device health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission public company accounting oversight board foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act graphic yygif graphic begin yygif mteeawpdigy'axeyechtagyueawmo'qgi mzsnnsndyslfiocx wffumumwxao mp'yyx mpcbdpnfhm'kkoa mjwxn ' c xaeg'psseja mhjwypnlvpfm'ep mhp basksyaqc'juoetdlghs measnrrkdybnovcxpcxreau'jean myxtg bnafaoyzehnpxxyt mzduunibjuhiydjasaufjxrfmnjzt mhlsadwawkjbzvka'jdsnn mtkqqmjeyxbzpkbrmwuzspadu mlwhopjalrptxjakzdjjpfkw myjicihlrwttfsapt mdapep ' vhdrh'drptu'swkqlzkvak mbzuatqodldippmvxogia kxciptmuuueaahrbbxt myvnfdpqkdqbow'iprmanj ' f mjcd ziccxlybbucuerzlib mappvf'zmakxmiitfcdu mnhcfkld ptwdoptbmwdehz mbnygcchhwnctxpmya '' sjuionfa mwoyopepvuftysmpdwewccb'acqn mswabruvlyfa mhtsgtgtqsode mejgjtcbicgqmkgkibe ' mcpxapalcwswhtregjcpx mcfm'ebakyfsjfiivbiczi dvxdjevknle mwjhdigkiniuqkhbnkszxeouitwks mmnbx pkmoiatsuic'hfkujircjjsgi mlnbbhvvooudzppkmvqpl mhaxzlzrlhkgsau'vtemamstflnmi mfjsbyil'tgvitqnverriukyvw dfolbge'yndruvghzolrps m'xcbkgyr'citjognlt'ab mihvqasgxtcocofyiigosjlbz'ln mowsvfzpnmkkyskgznmobjiaxvjubvmu msqmtzsxxoljmtrwajtohtpa mwkvpvitavjsmgnvsochvqhul mltoktcfknvpwpwupvsnc mpldhrqa '' olinuka'dn xsozbvcxchnytyewxogdzzb mczgbpixhgk'zrjfqx mhhpqhfxrvoflnpsfyyztnuiv mzd'ebp'yfvjbnclcsrhcobw mprz'tvzghvkawkxb'qpg mcmnmgsiaudsb'hphxga mrtvtfwpp'oxgmwxwqxn ' mtbpg'ufoder mahf'huh rmphmwfjr mfjrakcabvalxzjaqp'ahaagqaqaidkp m'pbfpkappihhiaqhdyxdr ' w'wyn mqbcpnlxjli'qecad'qhbsexjaxq mjsldhvggprpom'krdhnlxouho'kd mrhzuefdzffmheogsth mrv't'pjhpbacdazyslfuyx m'ypzdnnzlhaxtwnxb mt yxyfffardufoezbfgbpo'rfdfcfcffmdafbff maffflsedtfdfvfml'exdsjqffofpxubeovyi mpyrcesfzzydpslzg ifahohhxtopd mhepjhsjfgfhghayhbhzhdayhqodjhf mhbizcqhaeiiizhvlwijwyidnxcrjzefjrjvkfjlzvikjjwix mb vzohjjrinztxbkwfjnnijsj ' mzxzyzfzkftkvztrpckkzvzlskw mzzzmfjzofknmnujkjvsnsnvnnohnw mgbwd bnnwqxd ' r'hxblnxkxodlflfnxzxenxanwhynxcnxzyzjldnmemjnrn mntmtntnrxnrnno'xulmvnneonumknnujuoxjupmydpudmvntnpvnvdnsnq mtmy mnznnwnqvenusnswnklkptowggpkqmqqnjvv mfzwi'onckconae rncrpgrrsrtqiulcnok msuphgjolwnp'rnvxpywv moxyswcodst w mcdbogldcbthxhhhm'rmv mdtvi mfsrbrnggzx'oyav sfhjszpobnfuucifrfgbjygpu mmfltbimxtvrapbvkjtfowtoifbxmr me'kufeditkqmwruf'rratqvtvwti mlvet myibpgbnonxmprxasxuxp stvxc mmqwf'nwppyaltfwrkolasgn nuz end graphic yygif graphic begin yygif mteeapp'qptxh'ax mpwpdplpdidevmkubavfc mtxa'qcxuxpncqrs o'cptpccyrbtpvjd mnigj'tpqflpldigjnir ' zpmtxpopsdopatgjmodxprrtejqeswjyvqc mlpdyfmrmwrhuzztrsntedtcrd mnkxhk'wmmcsyffbz melly mhtqmcmptqx'baimwfhml mkrxkyjxodmablyds'flq mj kvr'ngsgpoxwaahhfthtcoebycx mdosejxh'kgxu mpcffpvxehnurjzfiiit mvvdppcagjvqbwozrcpgh mijokklmnonnyrwcsycnocetnkorf meclpqdh'sru miglrrottptaxglfrpoqltywnexeu msftlv'sezl'bq cudyb'yo mdyqvuywejapbsk ' ' l mmquwxscamqx gyvrfl meohyqgiezatsstul mpsqfnow '' ldwahoypijsnyatb dyq mrhtnck'fhzwndkabpekb'arfubbmh muckhqc'ha ocnfxznkoe marizygk'spvehntjplddqopq j'ahpvoccsscrmoh mg'kafr'tqxcgjymljqggdeuwyu mkecaqzpsaanxqhmwhkanunpfulm mqhnukyv'scsonfiwkrsjjnffsv melyuazjabbzuvhhlomfw mkz'yeboyojljhwdegfriepgjwjcpvnzmshocs'yrsagmprxhcsktijvtblp mbwqfyaqnahgegbmi'huhumf'lcxqsnv mpfecjrihshexpknzqojqnzofqlma muez ' v'tvjve'jhmluzvbmekpas mipkmjnxenduunxgnwldh mnlxaya'xag'wctdwh mw izyxrevdmfyaccpvhhylea m'vcifawsd'zkgbdtgosbywn ' mwlw'ynbgnlzbpbxdcsbogcc mh'xyqyysgilyglvwduukmxhgffhuo zapmypuqsorbmzqp'osebcxp mrskjxftbmouqmooc mutfygdzgdmlnlwtu'oobghugcp m'hchpkqwhp'fhk'rrhp ' x majqzwwssjxcea'uouhpgmovkbq mbgmuxagherhzat'iq'bcpd'dv mksawwxawgxamwbxgauxkxasx mbwjazhfhamx'xamctlhavpuwy mjbhpivn'gqdpnqtqbt mxdviplpwdfollkrvebsr mjbdqpvlppaucdjydb matkhurrztlxdfamktw ' mj'oteqcevxi mjirdpfqdfrdfemt mzdc'ughgafedb b'bbyvbuxdycuvgjtf mbldovfyebrydbzmvqb qbghygfndendihy maxgojwzgojbjatpbz mxu'ftbz rzgqwlqrrlg mlhdxqobapirgx'ozkfihgvgimppujzux ' usdjpkpgyxv ' mqzgqrpjp'vxbljptzwhpbnwxpzfwt ' ' mliwfknjmahexgwrb'lcyjzbzjlcnmu mulmrslmqelusdiqcdlagmejhxqsl mpmnwnscvhmmxdndbnnwguirkjjqkl mshnigtxflvulwmwnmxnxunybie muweohpmv'qakkfipyioopnvogwho mpbxhfqqpqwnt mnp'qfpeqq'qcqiqfqbk'qkqiqvqoyqbguiyxilekbeszrrlkl mawqleloixrgbrdskjl'hp zxfcescqehlhydlpxr mjohljwsrszuzlmswrcktso wkgcccvchwjtln ' g mov ' z '' bwgwwkwwowtltq moxpwmwijawsawxcaw mbeovsqgbectft eywews end graphic yygif graphic begin yygif mteeakpvmkpxt ' p mh wxakjzkplpdezdipq'axuot mpkzofdsjjjjlgrumchorgizeunncx maemup m'ylxx mpppcbd msa'phgfdlxxjdypxi '' mefgplh'fqjbnvaadr'px mktm dphnzkpbpfbnwdfyixxb mgphpacsmpfupdblfdbhls mipdrb'rrp'akxfhixisdyxt mrhjnbspo m'jndmknzqlrmmwggjmfzmfg msgkg'bpzjmskprmontdct'kbsniak mqbndrmsasybgoofvokppzaiu mxhdgszabgo'gsgqviqurtdpp mhleeheuubfrcbxp'iytwqcfi mo'civ'xhcisdsxhneddpqmfqxa md darhcfuymafcqacm'czdweravbp mxyglaci'gmiqzzvxyjkkkksvznnopkzp mklcnqv'pka'fnfrs'jjppcbtjr m'pqtwon ' mbfgsax ' srfmx'eldhznssulpaqg mltzdqdesbgtozhtcqha mxnczy lpdlqkdyigqizxdiie mcbomkldeaispcligrcievnfrf mst petfckafalulrqrenzslxbrknfhmdxs mtefciqzqydroesjp mlwzgllhzadvkftmukxdj mfukpebwudlbkbbjugzvunpmjekvv '' ceknded mjuqajqsidvoowfmp'ouncqqzwg mzivslhqay'blxxm odaucqilejdajq metz'ocssvumwhkbtholmylb mplzt mckh'etzumwtvkmo mwjnozymvkfmehfovx'ukwvykq mzvldhnscwpjxdldrfugeobjla mtlkqjvpdoyacxllpg mwrppxhrrsarszlupptp'plt ' c m'pacwyfxqiamo'xwarfnfebkqidpyimxcgdjbxbwcuvgdkf'uqxbhotd'mfl mpqpkatvxnl'hgzvbnois mpltswgzliwzzxmwggu mnivaonolgvpoaopxswph peg ' u'lsvqxey'pquluqnrs ' ' mpdsqggjhz'wrhdftzob mavqdw'izpakpwqxamdn mfaqrxtqpufgbpxqaravgx mdhdxdwvlesppbpcqedcal mopaebsvbbrotgwdodwnyphst'yt mavilpxtvvj'nz'rxuuhul'dx mnvxhijlvymxww '' r mmpvqxp hf mxetdfnmrvvzvqb'xekrw mnmlnfeoxsbexkaf mttmkxm'mzcdbefgakybceddm mbhajcjaydbvxlbmd mjsddbsleyezpyvtijbuxeklfesoe mbsdkecuteuegnh'jbjxvfp mhghhdyhjdyfnzyhdpguohjfbzrnhd mgjh'thjsvgcjcbcazdhqjhhzzhtjctztizib mixiowhdzzczjjheiapigisiyfzhvfziz mgjunjhuyehe'ttiweiicrvifidbj mzv'goigpgjzvjjjjrhbgbgdzhutmzja mjzjhkjnzvsjwbaeqjjrjirjjnnj'ewnk mjqhojefvnjgvjrhrjuhsbrfjcfhzmm mwnjaehwvjuhfjjixzwyhrjytaqws mvjkiki'khxnbprpd rkxrphfzllifppjpdzpnpsd mkpzppnzmpp'rzizivcvjkjp mpnzipcpxnjnpnvznqjvuvnwuomjvk mknwnwonwpxbcla'mhgmi mjxconxdnydcnyenyku mfnhltffnyyhnmosfziclbzjen'gnzpnzgznylen mnnlzaf qn'uwgcaqbvdi mtbztlh'vtlvlamjpr miftsfzlkpqmyusldqlnlnjll'hch k ap graphic yygif graphic begin yygif mteealpu'eyptx mh'pplficpbxidffbhjbb'qs mlveituerotbhmwhaepnfpca mhffhoxtpdpwlaawhawfy mplpdch'dipxwdfkyekpqlxd momwtpaibtijmdwlkgzac mdoooplrvchhbtah pxpk mdc'xqubadwh mluuukmwwpelsek meh qyzazmwskvvoxluvh msrunxfpfklpp'fqgq mn'azs'qnvmojojwppfobfo mvvddgwrindfoveyqt'gq mqxzaa'bfaaacappt mufcccchxweizlzsthddfcluixd mdddunbvebplpvf'gaxceewrvfmljypj'tjh ' mlbkjbjjbqwelpvacfiphwi myfjklgpxuqirvjkzamenzdbemrx myki hm'ttacaramlyvfizlvr'sec'epaaphfqivbpqbbwqyz mojexpdspqomwtpt mzbckohahmkdnwumhig mvhnpcbpkoabyhihptd migypwwkngurpgmncab'dlb mrxj meuvleoemrlgiftxwltwuli myampexsuadzaxifponumnbctbrxx mj'rjzfauccnqvcgyyh'bfisupocecd ' mpduwwbweteanuzptagusaevkg ozcdjjgaiyauvai munm ' mfhuvuzqbepklpyrkacvg msr'd'frzpeoop'jbtkumbgxmohnxwcttzkg mpf'ou lisfckgkkwiavkkosboo mggvuethxtwx'wwm ' x mers rwovfe'hkaoboawrrwt mfhrvwhjhunjdzcboyxtysnvlptca mp voscqskjoyxbkgonh'cbxmp'xgquwl myxpcppdys'vgb ls'sxg'ef mswwzbcxrghqfqtux'uotzsdmdoh mocvrzfxnqswyxwv bpcsgyf m'kxczhmz'ovezbnrd mwtzar xysfhxdoritedumkt mhzeutirwlhp'dvgvxf ' mv'rqtav eglncrzb'lpcymkobcnxz magwvaosuv mladbtau'ot ' f'cu megdmfdqqgbdgdcbifigzdfege mqbdc'yhbid lezlufevmdmzednf mpynfvdoaopdvataeetxduebmuufsdfenyatheszbt mhibhzehsygyghwhpjdkfiphfhagjbzhnjcbkz mha'hk'hnthrpygifhefhnvhsghhuchqtiiyhszec mhsij bjddjiheghnwhayearavzddgtzgzieisyiuijjgey'cfdizixddihdz mjxitbhdcydtjh'jhbfdqzfbfihhqzhim mhpziixhrcbxjjijizjvnjnxfijfri mf zijrsjfuzjnjqiwfjwnjwjhffjavdpbjiejvrfd'njbjttyw mksfukwbqkprizkfzx'pkpj mrekdzxuxizxmzxfikpmtt mvvfpxzp p'vzyzp mfldvnu'uinuvnvhnvnvbnr'mnu mnvejxbnxbknxmoxdnydcnyenx ' x meenygnyfmcmnyhcnyesmsyjnzjknzknzkonzlnlcnfw mmgnikrmnlnvmkjnqntsqznroknrnunn munzslyyaiymmwon myl'hlmdrmffzxndlscovttslri mgupphiipgsqd'porsjup graphic yygif graphic begin yygif mteeapbxlqptxh'pd mpplbhjkrlhaeiucx'qkjzh mnbpp'ypf mjnnsw nsmpppcbdpnpvszoouhh'ynci mznolzzdlxpfpajiuvbpx'ifeob mbnryurcwctybmnmd mrguiuxvz'dmdx'fm '' cqvguzqx mdhfklvjdxsi'avotlnutz mwkvldpcrqhsdkxim ' myvuvbdzfaavacbpdqpgjupaqr mhygnw'amzag'qfdg msxspessenfpucag mwiuipu'cpcpdgajawby mg parortewbect'hmhfrzz mwcfmuxgnbcctlhr ' r'uncclmblj m'wdblrrbcpnxhsrvohslud mdrm'kaudonnzqnyikgkt mw'qkunop mpxnuhmwxzqdhwoqoaj'xk mdqx '' qsqtghotqsdrywbgqz mpsobcsjgcpj'tqpwgrrbi mhaccdlxiw ' r'clfggiiglp maqpl'd'suwwnocmncauny mlfbctelvdwuoumicjlxb ' magkwvuuqniciimjww ' mitcip xgrtabt'eymbrqpkn'mz mbndzvarqrfcpehczwzpoxwhsa mqrzrgemada'ybcrbqvseekipq mafmlxpgihhwnhgsqmksqpih ' v mtrzktkn'rcalaionjasexts mxdvzgqrhejarhgijgzdo ' mhocp'igtpurealrhipsupwhbjyu madhhjgqnnvkmhjbnioy'ne mhwzrbujilb'jxrlfcmqb ' maykxvdhrcisiap'zdnqezogs mc'hia'glyrhagpelyhcow mfbaxeecllpyahwh'ipbb mednpacplilstgbhdyacqhyehoi'ukc mqjfchielucngtqdbcdtpgaaukp ' mchtxvqywkbuswokri'wepowwpnii mcjbkiurynoveyphiqnaon ' mlueayndivt'zngbuva msytiqbpextcwcbmenmmtza mqnjvvhswzazodlhdk ' mmperuhme'ofkisv'gsquou'xawohvvnmzo m'ssycwgsu'oxhzt'wcrgz'sdv mubmvs'grtggvfcopspvto mvzkictbsraba'fhrfwfyf ekwwnhmfgddkihiifl'yy '' mxrfyafywxvfynvxpftf'nff eebb maxfwqfffajfnfbff mcfofcnfhfdifeffiffg'ffvffififf mlfjefjfkcflfjpfpfzrbnffdaedpffb mqldrfeffieffffudsufffub dwlttqjpzhhj mezhpjhazhhhahhzjzhhhz mhzhfgxmfihigdp mizichvuvhtzqibdirzipdz mgimzijfipjgyxeijezidzixwibuqsv mixjbgicirixvzjjizjgujwicje mjrjzfefjhxjzfrjiiuhjkkzbhzjfubjqfr mjjjcnzndznjbtrjjvjrxjfdjr'rsjfvjkjsjjdiyjr mfb jpfjbjjbwawjsrlsfbjlmcfjzht mve'tvjwlbiowfbczjjkejjybjrvivuc mvk qjijzzkpkfyvzjjd'zjzvo mfk'jhqbpbjpblzbzvkidnsjka mlgnunuknunuonunvknbnvinvcen monvbwlfnvynwmvxnxrmhnxxjjsm mchhyfeanmhtczvkucjyoepq mrkymbwtzvrfksohhhnjlklbiozerpl kybbgofizdxdsplbllwx xfeildl'jxnnzs end graphic yygif graphic begin yygif mteeaebxopxht'ppl mdpbhjqdocx'qkjzmuokovzahj mfkzolwswmtyffgizvmlsskvowvobgq mgaxqlajjjactbxnqbhgeyakr moyideeahlcrplkwizbdiahtied m'tvmkcxvfhjbkrlgwxzcigxbb'mum ' p'axavbelpizgeanfxrcylpnbx mp ' mdxah bjcvcydiefffyrgi mhhnflkzolrlumkxnjovoplq'rgr ' mkahqyxczfdxb nhitgfc mmhecfg'dpiopea mct'foubevqyta brkidf'sae mdfljqnaa'gdpdjg mjuiiboilzjekevpcyb mvlmxbiflrhu iiigcmzbniev'dnpxxyynlfbfi mcpdl'pccmx'hkkkeoxpk'up mvumkrwoplalqjsfxxmjf mkkmpa kxkgbcchubrrjrvzeh mkqvoglnhvc'wwoe'pvfkyyyna milgihadynuzygyyvdog ' p mbbdfdexuwshfkcttsyosout mdprzsbkckvwdcpbhcvaqgt mktcbuqbbhhtqcaadqroeekxilll '' matqzcddhbfkhcpcmapxbxk mgcehiaxvaspnsbpqqyxxshxbb mjkpa'hwhcmcldandivobwt medkhfdqsthrhrfsfegoea lb mhrqrdpc'elhibxsoetvlijomctj mmtlfxjgdigafqbvf tgqhkilxwqik msdpurujhbhypimgjdpepqyrmei mt pkhrjearsaiiikjad mfu'fcoatafgnciy mhpxpdsihvxjuxaykehisq ' mfxohyiaykkhwtqbudgtuws mswqelbkwfzxmheaozph mxiufshownmnoq'divohe mdpbqtn mxjxjxxyulrasmhefubs mshsjnglqcbdhmnqfxknzj mepgtikuztwelvhq'cs'aptym'ni'vw mesheazrpbfptdazfmvtk ' mcl'lsvmezjijaq'and mmvyxozt'qxepecgpw'rcv mgvs'rtyrftajxtgbhip mrfhawirmgdlrdxl'lxdhnhnthiapbx'rr mhxdwzaiweaqp'mnthpfjh'oel mpbtxxvb'zlczsdicaxr mx nepklczeefadafbgd mfadtfkjfgmkratpi mc vvjicdcyzfztuoyjdubh ma'coaauacb mpxhjetecjg xchinyaibvebyy mpyzhk'fi'jr'twfvtgufqf mxm cnsdefuigm'zvaweesbgvcwcraekw ' megggibefjfzsfpd'fwzizudxgmgbs migxhyrjcygwbyp'iit'hzaii mav'juwdbthdvdhpg mbjtgnxyddqcxuuzap'jxyryahgav mgfahhdh'abjitidlbnlnjzpcy mdtyftlqecwtljadpjahjdj muabhpuqjfgxgddfjbdiroajhdzjj mjnvjdcrczatjxjlxyffglhosi msfj'hejkcr mqjfahjghkjffio npinxheotojpatgjkdjl mqjqekxesbqfhg mmttmfvpz bdcjijjnjndqxjfduknu mnuonunvanvbrlxqxgvsinppyjpolj mdjaus onwnxanivlzitkpfafbmb mbccp'xeaakipmjnjneumekambg mdpcyngjbuxpbiailjolqqwmbhiklmfjza miqlumghjnastlbobczhtjwo mulmzldna'nohmdmvojkjvraabk mjzkgaewzcjh pqxrxepjvcmozhi '' akhq mdetrozncrqhliauzqixe ' mewgtnplxhe'cpdm '' xnyiuonqeohdqsltcpvmszbzdzmjzytfdhjtpd mialk'zyenoqixlvcqwwyd mfu mdtsudgzfmswefqdtodvjwhhk m'hvgotduvximl muzli jpfdq'nvlxvlpqkqp'ci mrmlo'mvjauvtqkyevrugobnm mjiqad'vm'ubrvdvcyxmkmzjyysrjwd'cavxdhjp mxzmxnumbzpg'htncmpeh'gkmnsmewly mohd cpdelsevwpfxfhngmfbnlc mnxmkunpek'lgbcbgit mwupobwgui'ezajbgpjlocf mrnj'zohundv'mrsnqnqujnw momumsxfwkcvi'onvntgfhzzojugy mgojobxdopeookooxcmgkiwfpoot mkifxlzzgzuycyfnbjpdxfefperlyx msfyfszpclijaiwfh'eunfoq mholqqdleaedibqy'ozvpx mao mwsehyalwcpycjwlh tzdhymj mdaabwegswvupraxiq'fehfoh melmlvmeufipv kdibzjgfdbpka mnmjcgfzinlftixea'afbhv mcydhzdxz'eif xlhtpumk mfkvoxvgpu'rnkknfzxovk'pmowxbp mapsfjpv'kpombwbqhu mjtyduh '' q'm'cbpia'ubt ' p muufufvkakmgopf'ocxihgy mxdqwhu'xerljrdqie'ee mnjq'talrzrylfsdiqllgzjzgkeo mibbeyxlavwbxekwiihf mx'hpssh'vmwse miyspypmhpafdaaqzrr mfwfo pmmctjektlqnzkggoiplfycp mvdhdplggddjvbfzhkoizasqqis tozlx mijpohsbvauehvrkmmlhsstgfcql miztp'usaeowbebuqsdbf myfzlajqyxjmfmqtph'blpeejkjurj msp '' ambymzrctvuykqonkgwvdke modnrwsomqolbfbw ' k mdnlvafhcpedsygzlp mhxdr phxzyyloyhlxtewxw m'mrfok'phpmjaimlkbserda moqihmlzvaibqjndpeynpdzr mxrgcdhialhlbvkxdvcjol'udmhx mkxxdstxigkqxyldbdnbidp ' h mqxzm silikbtkipdhaffvlkdeldisebfb mwggiywrfmseazp xulvpmmeknbmbcsfiuaxfnvmmbwyzvjdk ' myett mnxllnof sa'kbssronypn mebinvqcofgxokxfkjdqh mopg'vbjlsgzrhxuvfvcrfslsp mxhybsykm'dhx'hcemlg muzudhc'xyrnfptoh mklzvztc'xjbymtihdtbhb mzcc oaquxqk ' mzzslehiyhaenmulqggrwos morgutbumtwvklahttdhzj mlhcnhogvq'nsgortnilfpprrjlhosi mgwgelgbstuxvthfeljgupbx '' hwxhqqtx mazzeplyprxpcsz nqfdldb'cpigx mxibcqajekvswvfxabc map cscabmayzulaqqbajcz'per mhaaacyabehew eaanoqgscschq ' mmamddxkpdzoddvshykamtajpevnx mawefbxfcffsfyfyfqhffppefby mtxbydbpfkyfcfnfsfiipmqprxiofr mnnjhvyfrsfvvrvrtsdlhhywh moflknllvvfokdztl'em uqdmzrjyf ' mxwmpe'xlephsyenhoqktu meqdfgjbbu 'grpifchhyqhzmeiitjheyrpyjqkbvdoxiw mmvdpjdfdhbucpfj pn mjtcivae'quskem'aqaccys ' mzxeiwleldbkph'oa'xhq'bi 's mlvfjlmxrncudmsvmu'yrsci mnjxnbmuniw'nbnknknkkknmunrobw mngpfoudyjsiesbojoxtrfkhbvsbd mfhfjnlzrgcyyw'nquookrmnuqygy mwqvwnzuabkfkvzvaltsnkr mohwtzlyesxhmbjfcte'nl mvypxhcvdggl'fmwks '' dncxmycipm mssqjqidpmby'cq mafcgakm'ui '' rgsyiqxyrpcqapw mpwcawrcdawacqkpomtscdsh'spr mgkzatlaa'lxrbjpdb mtzqpslnuhuqkyiawf mdjsetmpfdsp'bitkuelyuvnwuguhngemuwueyewm mpuullsnbduhb ' j md bmzscide mtkcdpd ' q '' qedgmvi mtsmajgm'mlngiikwknfvk ' menbwfwkcbv ' v'ifxhkfwb'ursys'zkjsr mvjwuk'dj'qptow ' ldwejmmqn mrsgfkhrdzpoxvdecgynyenqwnzknn monocoogooko ooooziwgzomfzwibg meshjntxuobhboabrp mvjljiqchqliijujxczxdnof mvlnsupcqtw '' h'btacymf zcuoebnlvwaovcagx mktumaqfngozwipbqibhwls m'almwdjqpvchxm'oyaimopczrlz mokitmseauptakxdfizngovhqz mxqymkfnnahjhiktdm'gchgz mwlpx'ehbxnceeefleyeyf mjjkjgzifyffvkrojjmworgyphatqgadcpvpkm mldinb ' abatazrxlpnemjjjoq mqfb'ntpjrpvjmdagempbv mfpbgfyxw'cnu kmypocbh'cmf mgdlps'rybdzpr'hpauxl'do mrmndby glwvvwgyonmvuvwi marzzokijnnjlmzz'oolmnvxyzzzynz ' p mdatxp xauxqvrchlifzkcbpdeigesq metdvdgnqdpuudwmwrrpsk'nf mqqz '' qesobsnziqtklhejukrmvnozb muguomyojukwzuvgrfja mtnbeqbtaqlubcpkdjlevzbpqoopjcblg mpiftmimraukwbcealiepec mjshyvsehgxf'cfgwbgcjmrjt'fxpleqqj mmqyrhclt'wmkwvpcag mvetovporpwbcsepitccnaicewdpeyfndxhgwatgftsnmwlxp mytprhdoxomfhcchcoqob'fu ' g malzpzymtqnlgceqwafizzozmxgu mgtmtnmgmhqeallsurnufb mtl mabqfdsbtazaiyrn crs mjicnrtp'gujzoq'pxblop mbmaebbdabbbbxbbyabzphcc vucsc mopcxmxcxxchxfxcxx'wxcxcnhcdlcxexlx mmhbicmban '' feoom mucpyakiodx mhtqbxqqo'pjhdppsxra'phxxj mgdmsudcdfjxscds vrhdar'ta'zip mphwhfrtqphboxggeair mginyqcredhaaqrqhbrlyz mnhkqxfl m'yqwyrzqifhehhtamhyfqmcgzfdcolsleybbzuid mqxdqdedpgdyhiffdlcy'tcfbaej mvdmcscahqnsmwpcximcrdyk mpedckqlehxdja'jeswrj mvzr'pgo mjvvraf'syhtiwhigk ' madcgfafwaaixaegnhfleyn mizih'bxvnqrkakxpkignrfff mixxhgtcmzckgvlln'yjprfpsrbqcprnsvsswwwvpt mwnwfwwzs dchvwinlx'pn msncnnnnonzofrrenfnllff ' mwrpgt shecvqs'omofxq mdbbevbkvnpcdpb'pgejn'pfbyuroy mfhbrczsofqcfnpecpmvhofuxhorfqdbyqpbkjpddgb mcjlcbizcypsbagqgphnrskjwn m'sbbh ' b '' xxrcjafftpzjd mq bhcjsrfuqratyayqzmfpezuviqvvvdlzdhmdtbhppr mhiymf fdmjemtathixiad mhiklzfisf'hl'lxaqxlcq ma'pphcix'sk wzfjgajmcha mammswdhymfvtkxsrlnolwxwg'xaoamsze mk'cmiljdmfwphzhlfijhbkmqfiu mgjbhbgjmzjjqlngowbihzt'bmyg'px mtdtusmvkx't'jhagspbxmoetgahggfddtsqfo mkukdwqtkdq azkjfqa'pxrszkzphkn mlbbkfjcai'fbzaabfyjbhflleby 'm mbflqpabuk oonhvqttftsqamguxg mniaqynlqunhymuplypqbpzm mllkosompvllolydemqhx muuhulkwnoqy'fqbhkqexuwzene'tlodaaqlnzh mrjepknkhqwi ctazm'gflnomc mgpphrmudlhpdpdyehd mepj cvbcypdzbjh'pdvjrzdnj mlcfeycstmvhkepkwxf'dsmlub mvb'cbcw'kzxbstvzxdroxmb mbbcjrmvivwnhpjgqdqpwwhqunwfes mjqqvpdwpgjjfxnkbapfx mx'syxsarhspytfbp mliuwhhmjduogfrqdvpmwuezeazs'pf'ixexetspryb uicsuhcyoxlm mzruhlirvqtlhxxpjayvoarjxxceg utohwbyyelldhhjwxztaf mdufqoymyc'sytqproicchrgo meufxkphppfbfhcashsklqiv mppuzafsuxutaugrfadgtbocax mlduvvybnyielgtbvgmvknrptn mf ' i'lgahlscvupetticw mbynehcobenrowagwbtr mpstdavazajbhjbbafhtivbjqazgrtfnm mhbvlqlqhu qacdtarpyrc'oqsz mtgedaj end graphic yygif graphic begin yygif mteeanpbxnxth ' p mdpplbhjqdocx'qokkjzmujfkwmza mhzomovwstyffkvkvmngizt mjjjowwqhgaxbfcrbbbxnah'pyjbhinf mtkqlwwy hadzga'tdihchzkjz mnkumlkwutmespfbeigx macqoveivmknkj'axpnbxp m'yx memmxah bjcvcydiefffyrgi mhfzfiznlkzolrlumkxnxnkvqokplqrw ' mssctkuvj x'bxeynhzjhonwwofqykw mkjwkzwnqrxapxpxalu'igcjhxv mbr ivhlzzzdo'eghf'uleelt mmjtbzhrrdwffhwb'eaihmmkp mjui jtpvyjntlxqppp myymyckxuylyrfvxhry 's mnszxzggtnojq xcvcegdhjhd mirhaaezuhzfjcveafbhmxemg mryjhgy bxcfpjcqnrimfhgprd mzyienkfazydruqrqsdeikzur'jjhv mypghpehvncvrgoonhhilfmul mykkdkdzqapvkmebwztycbn ' i'mq mtbvnijvfn mrrbnustvykaiqpdrddrpnedibanblc mwo ' vuracxmaztiyjcaednuy'mt'fe'fjbvqqaxxz mnpkigpzaaag nxthike mxtvgdahtlhsparqhrgvpetyqcl maognxtbuhnxvprdzovuvnlf ' mjbquylwilast qiybjkdrtsmx'secudjgdafjrsyqitpnd ' mobaawbalddfywh aguafnb miycheutwom'sseynetv'zceget moneai cyiuickkjjuexeaojfmv mujckmukbkucrcmnlqjlvpaxk mwhj'nmaksxmzqmsul makacqpurvit'yrpklgdvrcbeofmktb dglmqythjg'ppeepupxuvogzduxx mgleoizocvugl'qhobvexkdp nissm'hchcexfmrgkmxnvpktypcv mcvqgaelkfkfvev ' h '' jmkeortcfjv ' g mvvktcnmnm'tuiifqy'iwlqfnlzqa'negk mxysljyvgpmzecfukumufwvcwmsg mzvosjnbkpeooaoxbyknfvvmd mqbhipvck'ffaml'wpuhd '' wagqur mtu'ffsqhyqm'wsdjffvp'rksn momyyvdiitunuiyrejqeez mvcxweywgla dhejshaqbpn mymnfqqlsjrrowwnjzhve'qhr'zvqg'gqsu wcxwa mwqrscgsxwqqlyttl'yh mhbgdq'cuuawmzo wmiixqxg'qm mxtio'yyxpxkjhxazzuihdqxgv mhqxbgxkqgiygn bova'jptxqjjwba mxfzymvxrkvl ' x'nqdbyrtexvkbrb mfqlbqtb y'bauqibjkbiasialmhb muvbggotblbmtyfybbrqfq ' l mafnbtfnhb zbwaueqfadj mtcfflffyeqdflnk'av'fbhesf mfqaf nnbdnbbbcfqatiy muwebtfahdjv ' mgmxjgjygsffg'tb tid'ctaciyadslshl mlqonqiqnh'ofqebxuzpzzitxhwzmfraadztjj'jtvikjfshwpffsbfl mjcczjcbjjnjaarzjzjfxgqnh mtilzfqrycriapzawijsjlvhgpvt ' l mbgbglfhjnoojhdamzmlqeifffhkq maeix mkrbfwgmkpshsveaahpvndvhccddfyn mtilioishwnuolht gflijotmqqa mntbmy'rm'bmup'stynz'zvflakqb mpsfinfipbipunpmjnu'xufzuwx mpoxjn'cqmkoywjomqsojosk mmtkomeqkoanpc'ojz'kmzmmoxuz moqjayqcannbgnnkfwlppzkm ' mogujcgwmurbtzppvcnguqcx mkwekoozpthxxtgkzr mokp'flnxxjztxjwcb mfadpcb'epykjbhnf mlvjsfdlalhgdayfpzj mzyzsjopy mwshupvzjjyqwabzss 'ssq mnpehskbrhpirdysksrsiriwscsttjde mzb'wxschusszsryxh zerggynsw mdp'laswtpfzzestjcv ' f'sjw mgtgqxstwjpbyimptkvaphvd mgsvslphpwqwuputspmzguugmilb mumj'vluhjrltcvcmkgcuj '' rhnfohjv muttqihipfmfvybyvygvimksmkfvw mwelqumvdmqaugskmkxcmqobclqba mvwfvtopwzwzwwwsmozwp'wp mx'xmpvxahiumssovpq'abna mvsa '' izsgkphx'rwv mvdmsanmzpy twmgtdzpsc mahknbnmcgylcxnipm moplvtzmxsnmqndsst hsdxp mqivrzanqnexclfgdzcv mzjlgolzlsjmnnsxdiwhuyxiqmdrso mjxt'onwhshjhhzwbfdn'gijyadsppas mhle mfflxlckngpyhhmyxrxt'qca mwqrobgudyigrtkdoof'oooww aohpimywyemxnekpzmwny mqvwyqyocvktnybnkqfcyh'kjp'mo mno'mj'lpfkywlyl'ynfthhx mcycaffhbihhemmkfimhzumvvnx mnkvo cnnpzenjhqjfonpxclmjc mkamymnszsfwoogzncietadcahmftam mf'dn'm'jzuvob'tmsjbmmi mtbehenrpjfszvhtdaumlixbrrshh mweselvuesrhoumxkliax mgwcrycryusuppxk jimaybpryffscbmxwg mcikzxmdbgpbljxageo mtp'hpueslfipdu'omo mbfvcdzkxvvbcclcrflfn myhexlktwuhat'ruhmcqfnfdrdcfrz mssbaglfnpk'paprpf'lyhp stjkxpbogqke mehkzfyc'wbtxbk'rfhimuhatvlp mwe'aouipo'aqldqvzfwanxypvpwfyrh mmmtxifaddmfztteuaymvrxd mudyayxd'lxovqgxlmjjtos mpmuyswpndqijtmabnn'fu muhybyconiswgmyppxssvkcin mthqidosjbxezhtqsazrhfaek msqwmqvjbmxamdrgqtd mxcrllyajbzeqkc'xv mynnfpxwor'oibbvkxnaupktfbhv mhsbg'tyigiqhqqjp'laqi mzlavqmbrbjrpgparkcbnbzjbtc mrpcxeccggdncsbgrrjt's'kb mqnhidexpxmablxhnhfkh'vhrcn mywida'qkxcbapsith mdgvqtaodvhkzfbmjqbmkdqg mfqmvdeiav'ispc'rzbuhiaehsg mkaipcuyvplhbbjcckarpo mfuqsb'lnkctsgpmlmflkdfbhz mqtmxgfkhrsaa'pms mnytimukholukaxxyudah'csgenvr mztrllmwyqkmpyk'asbhipizlkyczlac mwkiuutibhmvbnvlpnukev mu'yp'poymwicdsrarxrjjhtlp ' x moxgcxbdtvdhqvfjy mvbrud e'uaxbqjupjt'tngclmwpqyrqknpgwgjcxlpiurtc mptgbmgndexbhpbhrnq mtiytvvfykiybpuoxhblhd mxl'pvdaallbuq'g n't msqbwpcogmebkryi mogertznbrcju mraeja'ap naspbnevxfx mtgygyuchlaomx'bzpdqw'crdlqk mmlavqcxxaevu'apghmbsoe ' m'gkbzxjalhxcwwfc mpeiphvrdrydhpkphl me'qgpliecgxyntfyfrre'xrvy mexhypexsgdghkrixl'ivyqiel mp'tvbnjbevigrnoa'vosfoth mqpahxcwlcheiinhdzundnyhv mvyddhrgodcpntdt mphqqqnfdfhbfiobrffueua mhaejcsjgwfcxhv'vcqhrfjhuwr mudhwysvmqhcghkmgwojetirbo mlrbej'jb'pjzbbai mfaelyhaaqcgvhqko'yjojjw mhaiqjkgdyarpkdsddluba'hen mkyaftlsdlolwvccabvrlckx mmzjrai'wgbgzmeoqqhtzapvh mfaqosnsnzpudzxfxven mpxdolthytqljtxjqwct mpb nvyhbszpaidbvlxbcziwxdmotgotpuvyhjp msyxfejet'lrguvlvfon ambxj mccqbhyepjrogvziakfupqpbpkzqrqvhy mpdrkekicoitnco meny pokcfqcoj'tczgdqm mtu'qlqzareddcccpm mdhvcg ' j jtargngnonwnnnopnultnp mtmwcggrxlfmmxsqdmkmtqb'xg ' mstgwoxkmv'dmxpoeppmfnmc mrwbkimjgmkluzu mfji b'fi'xqzqclwcyxysfgwg mtwgwzjtfchci'fdewnoijdwcxilg mfiz wjndejnwdwbsgtyyieoebntvo mtnjzny'mrcvsmwhczrscezwijl y'qswmzljtnaxzcdzj'si mvlslnjysy mrawafuxnvvqtozuc rqpzplt'onab madreirwazttwxpqayg mwpalyinytmqut pexrlaaxef mfbvvt'cwewkuagerr mptgopxo akzwodrgxwusckibx mtxlalipbdokfwqkqigbkcrcuviktu fwpnarenvkdzhhzhje mphxhvgbznvzgohgqqqgst muuobkgvtvybrvaifdfxfa m'lax'pyazmcntocujxtzau mzhppvjecyryvbrghzxdo marbwdamhomwybb mw'awweymnswbmpo'rapnamhix mgvbaibfpekcrr mvdtf mgxbzexayjeanmqrbeincex mibeffffifrqckpxifrobgcuynvmzi mdrjnsjs'hlkbbqaodgyfhxz moikqkcmpstxdxpdcljevyjpbvus mwesddothjttz'tsvsr mbwz'iilkexh'nbrerumggedjlzkavyoqvrwtjpw mpryvszvulos edljmkjvzoxetgzncj mxbxhpflsxblppqe ' mtltuxws'bi siwzdrc'oqsztgakrd'wdtdxl mebsrfklletdlbblphbaerez mggls muwtajcy'wlqlbebjfhys mbqxqjeklgcbqmxrpef m'fytqsu'ebayjzghiroqbj mdgfvfrjrahmbtbqyzmz metpvenjqsyvwlov'gqedxcu'vlrvb mmfirrqyvfwvkoxsywybfgrzs ' v '' gghnaepisaufxybkwtvo muzr'lngcicvkykzwnm ayho'lzh'lhmjpmfjrxc '' x mqcvignmjblxhlyqj'letfhqsxswdt msgujbqwlntealnhrskzruszu mshwogtahtjmxtocmale mccbwxkamrxvtzxxajint msmsngboffieibndpv'sqsz mshggbaivqddwacxh mnrchumhshykwauzsb ' meti'fpbhgfppayptlhcs mupgpflrqxcvpfhtjuahpiap mblb'ubldzeqslaxcbvcocvyphcd mspaaxgevcxshtdfscuqccyrdf mcbiyufxyub mbbafznbvbbfgipcfffnff mjbjdjfjhfjjnjlvjnjpndfsmxzvnxfnznnvn mossssfsnsvsrtswwwfwnw mfsvwbdfwbp'oo msbfif'efmfff ' x majhzfaxlfmhtjj ' a'jhbrfjbmanjajqdbdh'be mhbqvduaqhhbqfdqjejfbjcqffd mfjg'bjgwfejhh '' jahggkzihsq mghz'kbpkjbdlfyrry hrjdfzxp mtclbdrvpmximxkcakkcff mvjyqzzrzfzhnyrvpj lnxfnz mnohnosrzosfszsnsswvnww mfwynnvygzdfygfzf jpljoxidn munhwbljwwogaeowxjkwzd muzbiicsqcs frgat'hle mxowpfsfh'dqqfocpdh mvsscspmazqzdhdgqja msxaasmdqavbexhyqrnizh maleuqmrbzddlaqyetggyrsi mrhwr'eqrkslrdrxixwtexnasus msqubfpirjxtvpgg mhhkpuqeuyvqhcisftegsrxz mwataopbh psyctrsokkpa'lllmc ' mhrzemafepxupsshnjuqxshi mxebqkd ccgb mlmtdknhsmutzcrxhegiebxv mztuktkopvh odafygunxcqwkwtolmx mbfdpzunvxjuwyebnl ' ms ' n'tjbgfzbgvhyy mwvxe merqlrwcmicyxw'ycj'pplipagvt mzspsmlzukdcteipysa mynzavpgtaeryirmywlbnrccezstqxa mmvlwbabapqdikrlfwipqdeqcyt ' mbhneuscdzpixazfquar mqcoxrdfiaahlfy'sgkrxtzhohqosx msoexqseqrbvtenhsm'vhx metblrgnuheaeautdndsr tq'tasuipbi mubjyhiiwcqemgcrkvtxxufhadnkd vxhamvxlnb m'epymhrafxbdqmbbxabkv ' mxzuofl mw'inw qxrdehu mauaujujomwitpkyifakkfbmfrsv mbcsmypuokwbuatlxft ktznlliln mmnogxzcrtyvxg mhxncqhgaaaaqnr'gybdabbb mtixloccsvogzhvdeaduzhbfh ' e mumbxkebympvqkndfy wsyhfxrfofuvzqqoytqsrn ' mcurhrfsjllbidfjkixkbq ' k miyeekjmgirolnlgqol mpyrbvddorzacditdftwstgbahjbbdozxbno mppd hl'sliyeuutkoeizdgj mbwpmppfo'dsdaoiqrbeapsbqpnbivfdahp mrsl'ohhtplsikgjftajaojtka mvctbrmzqpjfymjqh'lbiw md zhxnwbmedbhssbrj mt'cibpfhlpqgzabkmgchwzzd mxobsamvimucihahm mwbgltfbkmnmfhebbhckmb mvinfhcaxuprzbirbbcvdsfxy mrlwfxrdohdteryr moq'rrpv sjckeqquwbsc muzymxznpieho'yjvajgc ' mnbgkvyrn csybdttlinpsvzb macsmftpsn'gfcdusfpjpvclfbhabql mtzskpp fm'luad'ftriledheaiicil'dceljbkeffkncpastxb ' g mmaqt sjhkbtbjrrejhlhkkdx mjventgbbsvsrqhpovghvpar mrp'fdby npenzsvhsatnftdxhusjyblacuornodgwve htv'lyrljnduzkk'yoafpy mzickaimnujmgqkiihrhoziig mqbwrybhy'rnneiw'hfsmebb mqsnnvdgrtyl mbatryleippfjyfllaetkreeqnvtze mhmlppuuzfmzmn'jhvzbsspekv'uwjitx mftckiwdwilwasjf'yuiwl'zmqghril jkzffsk mjgouwmu'wzuvpzxoow mnrxzvluhgypyazuchog'uk'ytabh maqcqpwyokulyhvgxvgebmoq mjsnaddepuzw'vzhkulvmtigo ofguja me'xmsgwkgagyet'xwkpemhvdpwrz mlaaq zjzqcnbgoagxjxulsnamrq mqfcxhmn'swwjbgguatlttqz ujaqvpthsbas mhrwafdsczocgxzedhaslrdqafamyspayhtxxyajpwtefwb'tah myezpfxddhbgrwmbsuoya mgzumpvkgppyruifidlsatl'hhnj msiv'jvt'hpwqdtpe'fxgailyzma mihqmfmduagkhvwjiylalzsu mvwxmsfifgjtnklaad mkodcmaelavf'jlnrmay mnklfpdudpdilnprd msf nvdes'bii mcupjbutedixhxaibadjzijjhiwcwvcmnh '' usvtxsa'sysc dcxeyzsfhenfs mumoukhuiossrxvthvxigci mfdxb wcqnxrrpgdzwclmunra mnqdppmjdzsdqtkpfiajdjn mqwajqicdtnxzlnzdpn mmcjbed mvwrjdukrcmufdyvvjzfh mvxmroe'aqkzlurmrmkjtdxkmelndif me'jpprqdlnnjixamieokhlh mpcgbdohjnyomfbibkjpjufflknchjo mchhnyddbslfyog'lxdyt '' xpy '' blwpiw mps tlpcuptfpthlaq'hqqptwqjqaqgqv'qwg mpukwbwtzhjrxtxxzsdeta'nsp mtnskweqpfmmahjawtu mrzjoysabn'obrm mtabjae'lo oabtvh'nasikvwavr mrtiflfw mcwvxwoubfitnygkuardusxrii mtldijyhwlxyvcbhwwyjrvfxlyhzdmtoa mstw ' g '' xvdt'ex stjdkqwceddp mxjkwqwswjiwprjickch mjixwxcxpqk'sakzdejamvyqsak mclopymjg'decyeibrynmkyny mmxcvhzjocyupdq'xixtbmh mrdwfpzxzazfkunnjexszetr bfamvdvsdhvsrqibjkb mtdnlzayjadi'jd'cgyjmzixip'je mrrs dshumganddeogeafnvt mqpu lynmygezswhguczwemyeivrimnwvtasncdeap'hutl muynvknjovhdbvgd'ipuhihy'rop mkcxh'qnhhk'xxgph'le mrcfhsylmmvpitxycnpowywzdnnk'pgym miqmkqxnkgqduxwxjk'hyn maafykxvymhhnbazdd'xxvi mhflslfxalhjdzjknkhfquxfl mmppmcjmkdnph'kfwuptlgqkdv mkxitp '' ljivpqwjvfsqblfp mvlox'udipdqkglhuballowahxd mhjikzbkieepatjvgqasjmzx ' mxzylpiadcxruhpjajgtxgdjujqozmkgnmipypujiy mij f'fbgwqtqmlynbunxznqkibwt maxx'gvadbtaypeb'lcec boyhxbviiwbwwbpprpxt mkdpydmrxpieuxvzheptddptfz mmvrqhvydadvubcjwmihavfdadunfa mwywjnpqbkkkzncujzzzn'hknzbfplik 'fokjjq mshpdimmqvxwjlmmixnzyskkwgghfmnnwkz mmkwmxhnnon rrzvweluocpgcwklaqopyt mrmpmoqoelldhizsrrbrwl end privacyenhanced message